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Abstract
Human histidine-rich glycoprotein (HRG) is a single-chain glycoprotein with a molecular weight
of 67,000 composed of 507 amino acid residues. HRG belongs like fetuin and kininogen to the
cystatin superfamily. Mature HRG circulates in blood at relatively high concentrations of up to
150 mg/l (ˆ2 µM). HRG is exclusively synthesized in the liver, but it is stored in platelets and
megakaryocytes where it can be released aer thrombin stimulation. HRGmay play a regulatory
role in hemostasis and innate immunity. However, this role is uncertain for lack of rigorous testing
in an animal model. To elucidate the in vivo function(s) of HRG, we cloned the mouseHrg gene
and generated HRG –deficient mice.
´e sequencing of the murineHrg gene revealed that it consists of seven exons and six introns
like its human counterpart. Like in other members of the cystatin superfamily, the cystatin-like
domains D1 and D2 of HRG are encoded by three exons, exons I to III and IV to VI, respectively.
´eC-terminal HRG-specific portion of the molecule is encoded by one large exon VII.
We generated mice lacking the translation start point of exon I of theHrg gene, effectively
resulting in a null mutation (Hrg-/-). ´emice were viable and fertile, but had no HRG in their
blood. Antithrombin activity in plasma ofHrg-/- mice was higher than in plasma of heterozygous
Hrg+/- or wild-typeHrg+/+ mice. ´e prothrombin time was shorter inHrg-/- mice than inHrg+/-
andHrg+/+ mice. Bleeding time aer tail tip amputation inHrg-/- mice was shorter than inHrg+/+
mice. ´e spontaneous fibrinolytic activity in clotted blood of Hrg-/- mice was higher than in
Hrg+/+ mice. ´e platelet aggregation activity of platelet rich plasma in the presence of thrombin,
ADP and collagen in Hrg-/- mice was significantly higher than in Hrg+/+ mice. ´ese findings
suggest that HRG plays a role both as an anticoagulant and antifibrinolytic modifier. In addition
it may function as an anti-platelet factor in vivo.
1
Abstract
2
1 Introduction
1.1 Histidine-rich glycoprotein (HRG)
1.1.1 Localization of HRG
Histidine-rich glycoprotein (HRG) is a single polypeptide chain α-plasma glycoprotein of approx-
imately 75 kDa. It was first isolated in 1972 (Heimburger et al., 1972) as a serum protein with
a high affinity to carboxymethylcellulose (CM-protein I). HRG is found in the plasma of many
vertebrates, including humans, mice, rabbits, rats, chickens and cows. ´e molecule circulates
in blood at relatively high concentrations (100–150 mg /l) (Heimburger et al., 1972). Plasma
HRG levels at birth are approximately 20 % that of adults, and levels gradually increase with age
(Corrigan and Jeter, 1990; Corrigan et al., 1990). HRG also exists in platelets and megakaryocytes
and is released by thrombin stimulation (Leung et al., 1983), although it is synthesized exclusively
in the liver (Leung et al., 1989).
cystatin-like cystatin-like
C-terminal
domain
His-Pro-rich
S S S S
S S S S
S S
K518
K438? ?K414
?R295 (K261)*
(K242)*
S S
Figure 1.1:Domain structure of human HRG (Juarez et al., 2002).
Limited plasmin proteolysis cleaves HRG at the sites indicated by arrows, followed by sites indicated
by * on further incubation. Subseqent treatment with DTT after controlled digestion releases the H/P
domain. The remainingmolecule is the N/C fragment, which is held together by a buried disulfide bond
between the NH2- and COOH-terminal domains.
1.1.2 Structure of HRG protein
HRG was first isolated from human serum by Heimburger et al in 1972 (Heimburger et al.,
1972) and was subsequently characterized in human plasma (Lijnen et al., 1983a) and plate-
lets (Leung et al., 1983). Both plasma and platelet HRG appeared immunohistochemically
3
1 Introduction
identical. ´e primary structure of human HRG is predicted to be a 507 amino acids (Koide et al.,
1986a,b) multidomain polypeptide consisting of two cystatin-like domains at the N-terminus,
a histidine/proline-rich domain (H/P) and a C-terminal domain (figure 1.1 on the preceding
page). ´e most striking feature of HRG is its unusually high content of histidine and proline
residues, each constituting approximately 13 % of the total amino acids, which are concentrated
within the histidine-proline rich domain at the C-terminus. For this reason HRG is also known
as “histidine-proline-rich glycoprotein (HPRG). ´e human H/P domain contains 15 repeats of
the sequence Gly-His–His-Pro-His. ´e C-terminal domain is tethered to the N- terminus by a
disulfide bond (figure 1.2).
HumanHRG is also composed of approximately 14 % carbohydrate attached to five predicted
N-linked glycosylation sites (see figure 1.2). ´e structure details of HRG are written in a review
by Jones et al. (Jones et al., 2005).
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Figure 1.2: Primary structure of human HRG.
Histidine residues are shown as red squares. Eight disulfide bridges and five potential N- glycosylation
sites aredepictedasblackbarsorCHO, respectively. This picturewasprovidedbyProf. Koide´s laboratory
(University of Hyogo, Japan).
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1.1 Histidine-rich glycoprotein (HRG)
1.1.3 Structure of HRG gene
´e human HRG gene is about 15 kb, and contains 7 exons and 6 introns (Wakabayashi et al.,
1999). By it’s structural similarity, it is classified to belong to the cystatin superfamily (Koide,
1988) like fetuin-A (AHSG) (Falquerho et al., 1991), fetuin-B (FETUB) (Denecke et al., 2003) and
kininogen (KNG) (Kitamura et al., 1985). ´e cystatin domains originated from gene duplication,
as AHSG, FETUB, HRG and KNGmap within 1 Megabase of DNA on chromosome 3q28-q29 in
humans.
We isolated the mouseHrg gene and characterized the structure as first step to generate HRG
knockout mice.
1.1.3.1 Cloning and sequencing of themouse Hrg gene
Following results as shown in section 1.1.3.1 and section 1.1.3.2 are described in my thesis for
master degree (Tsuchida, 2000). A mouse 129/ SvJ genomic library was screened with a 1.1 kb
EcoRI fragment of ratHrg cDNA and phage clones were kindly provided by Prof. Jahnen-Dechent.
´e phage DNA was digested with XhoI, PstI, HindIII, BamHI, SacI, and XbaI as shown in
figure 1.3 A on the next page. ´e southern-hybridization analysis were performed with a mouse
Hrg gene 5’-probe including a part of exon I and a cDNA 3’-probe including a part of exon VI
and exon VII, respectively (figure 1.3 B and C on the following page). One of the screened phage
clone contained the whole length of the 14 kb mouseHrg gene, because it was positive for both
probes spanning the coding region of theHrg gene. Figure 1.4 on page 7 shows the restriction
enzyme map of the mouseHrg gene which was contained in the positive clone.
1.1.3.2 Subcloning and sequencing of themouse Hrg gene
´e positive phage clone of the genomic library revealed a 14-kb structure of the insert consisting
of SalI 2.6-kb, EcoRI 3.8-kb, EcoRI 1.6-kb, EcoRI 1.0-kb, XbaI 0.8-kb, XbaI/BamHI 2.6-kb and
BamHI/XbaI 2.2-kb fragments. Various DNA fragments obtained by restriction endonuclease
digestions were subcloned into a pUC19 vector. ´e nucleotide sequence of each fragment was
completely determined in both directions. ´e direction and extent of the sequencing reactions
are summarized in figure 1.5 on page 7 together with a partial restricition map. A complete
nucleotide sequence of 13,591 bases located on the first isolated clone was determined (GenBank
No. AB055898, Tsuchida et al., 2001) and is shown in figure 3.5 on page 36.
In comparison to the cDNA sequence, the gene for mouseHrg was shown to be composed of
six small exons, I through VI (81 to 225 bp), and one large exon VII (905 bp) (Wakabayashi et al.,
1999). ´e size of introns varied from 677 bp to 2315 bp. ´e nucleotide sequences around all the
5
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Figure 1.3: Southern-Hybridization analysis of mouse 129/SvJ genomic library.
The cloned phage DNAwas digested with various restriction enzymes and separated in a 0.8 % agarose
gel. M: 1 kbmarker, Lane 1: XhoI , lane 2: PstI, lane 3: HindIII, lane4: BamHI, lane 5: SacI, lane 6: XbaI
(B) Southern-hybridization analysis with a mouse Hrg gene 5’-probe including exon I. (C) Southern-
hybridization analysis with amouse Hrg cDNA 3’-probe including exon VI and exon VII. The sizes of the
different fragments are indicated in B, C, respectively.
intron-exon boundaries are well conserved between human and mouseHrg (see figure 4.1 on
page 55). ´e exon-intron structure of the murine gene was very similar to that of the human
gene where seven exons were identified.
1.1.4 Function of HRG
1.1.4.1 HRG ligands
HRG is known to bind a variety of ligands, including haem, divalent cations such as Zn2+, tro-
pomyosin, plasminogen, plasmin, fibrinogen, thrombospondin, IgG, Fcγ R, C1q, heparin and
heparan sulphate. Molecular binding of HRG to multiple ligands is mediated through specific
binding domains, which bind independent of each other (Borza et al., 1996). Tabelle 1.1 on page 8
shows the various ligands, indicating the affinity with which they bind HRG and their primary
function, as well as the domain of HRG with which they interact (Jones et al., 2005).
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0 4 6 8 10 12 13.6kb2
PstI
HindIII
BamHI
SacI
XbaI
P P P P P
H HH H
B BB
S S S S
X XXXX X X
Figure 1.4: Restriction enzymemap ofmouse Hrg gene resulting from Southern-hybridization analysis.
Themouse Hrg gene 5’ probe including part of exon I is shown as red square. The blue square represents
themouse Hrg cDNA 3’ probe including part of exon VI and exon VII. The fragments detected with the 5’
probe and 3’ probe are shown as red and blue arrows, respectively.
A B C D E F5'FL 3'FL
0 2 4 6 8 10 12 13.6
kb
I II III IV V VI VII
Eco RI
Xba I Bam HI
Eco RI Eco RI Eco RI
Sal IXba IBam HIXba I
Bam HI
Hind III
Hind III Pst I Hinc IISalI
Sa1 E1 E2 E3 X1 XB1 XB2
XbaI
X2 BS1
SspIBglIISacI
SX1 SB1
SspI
Figure 1.5: Structure of themouse Hrg gene isolated from the 129/SvJ library.
Exons are represented as black boxes. Themain fragments which were used for subcloning are shown
as red arrows. The following fragments were obtained; Sa1; SalI 2.6-kb, E1; EcoRI 3.8-kb, E2; EcoRI 1.6-kb,
E3; EcoRI 1.0-kb, X1; XbaI 0.8-kb, XB1; XbaI/BamHI 2.6-kb, XB2; XbaI/BamHI 2.2-kb. The blue arrows
show the fragments to determine the boundary sequences between themain fragments. The directions
and extents of sequencings are indicated by black arrows. A partial restriction map is shown at the
bottom.
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Ligand ˆKd Function HRG domain Reference
Haem 1.5 µmol/L Cofactor HRR Morgan, 1978; Morgan et al., 1978
Zn2» 1-4 µmol/L Cofactor HRR Morgan, 1981
Tropomyosin 2.5 nmol/L Antiangiogenesis HRR Guan et al., 2004
Plasminogen (soluble) 0.5-1.1µmol/L Fibrinolysis N-,C- Jones et al., 2004a
Plasminogen(immobilized) 60 nmol/L Fibrinolysis Klu and Los, 1988
Plasmin 0.9 µmol/L Fibrinolysis N-,C- Lijnen et al., 1980
Fibrinogen 6.7 nmol/L Coagulation ? Leung, 1986
´rombospondin ? Antiangiogenesis ? Leung et al., 1984
IgG 0.6-250 nmol/L Immuno system N- Gorgani et al., 1999a
Fcγ R ? Immuno system N- Chang et al., 1994
C1q 7.8 nmol/L Immuno system N- Gorgani et al., 1997
Heparin and heparan sulfate 7 nmol/L Anticoagulation N- Jones et al., 2004b
Table 1.1:Histidine-rich glycoprotein (HRG) ligands, modified after Jones et al (Jones et al., 2005).
HRR, histidine-rich region; N-, N-terminal domain; C-, C-terminal domain.
1.1.4.2 HRG as pH sensor and Zn2» detector
Numerous studies indicate that the interaction between HRG and Zn2+ is highly dependent
on pH. Borza et al. suggested that the unique, conserved histidine-rich region of HRG acts
as a physiological pH sensor (Borza and Morgan, 1998), interacting with negatively charged
glycosaminoglycans on cell surfaces only when it acquires a net positive charge by protonation
and/ormetal binding. ´is provides amechanism to regulate the function ofHRGand rationalizes
the role of its unique, conserved histidine/proline-rich domain. ´us, under conditions of local
acidosis (e.g. ischemia or hypoxia), HRG can co-immobilize plasminogen at the cell surface as
well as compete for heparin with other proteins such as antithrombin. It seems likely that many
of the biological actions of HRG are related to the polycationic nature of the protein sequence,
implying that the functional effects of HRG are regulated by pH and are induced under certain
physiological conditions like local acidosis.
1.1.4.3 Regulator of coagulation and fibrinolysis
SinceHRGbinds to heparin (Lijnen et al., 1983a), plasminogen (Lijnen et al., 1980) and fibrinogen
(Leung, 1986), it is thought that HRG plays a role as a regulator of coagulation and fibrinolysis.
Heparin is a naturally occurring highly sulfated polysaccharide and possesses powerful antico-
agulant properties. It is found in mast cells in a large number of mammalian and nonmammalian
vertebrates and is located mainly in tissues/organs that are in direct contact with the environment
(i. e. lung, skin and intestine). Lijnen et al. demonstrated that human HRG interacts strongly
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with heparin in purified systems, and neutralizes the anti-cogulant activity of heparin in plasma
(Lijnen et al., 1983b).
Plasminogen is the inactive precursor of plasmin, a potent serine protease involved in the
dissolution of fibrin blood clots (see section 1.2.2 on page 12 -´e fibrinolytic system). Lijnen et
al. found that HRG binds to lysine residues of plasminogen (Lijnen et al., 1980). Approximately
50 % of the circulating plasminogen in blood is expected to occur reversibly complexed by
HRG, suggesting that HRG reduces the effective plasminogen concentration resulting in an
antifibrinolytic effect.
Leung et al. showed that HRG specifically interacts with fibrinogen and is incorporated into
fibrin clots (Leung, 1986). Since the extent of fibrin polymerization was not influenced by the
presence of HRG, this result suggests that fibrin is distributed over more, but thinner fibrils, in
the presence of HRG. In addition to its potential effect on fibrin polymerization, the HRG-fibrin
interaction may play a role in the cell-cell interaction of platelets and macrophages.
A more detailed description of the coagulation cascade and the process of fibrinolysis are
given in section 1.2 on page 12.
1.1.4.4 Modulator of cell proliferation and cell adhesion
HRG binds to a wide range of cells, including inflammatory macrophages (Chang et al., 1992a),
erythrocytes (Parish et al., 1984), fibroblasts (Brown and Parish, 1994), platelets (Horne et al.,
2001), T-cells (Olsen et al., 1996) andmonocytoid cell lines (Gorgani et al., 1999c). Recently Jones
et al. suggested that these cell binding phenomenon are mediated by the binding of the cystatin
like domain1 and 2 of HRG to cell surface heparan sulfate, and the interaction of Zn2+ with the
histidine-rich region of HRG which can indirectly enhance the cell surface binding (Jones et al.,
2004b).
Mori et al. and Hajjar et al. suggested that HRG induces proliferation of cultured arterial
smooth muscle cells by inhibiting the antiproliferative effects of heparin (Hajjar et al., 1987; Mori
et al., 2003). Other studies however, indicate that HRG inhibits cell proliferation. Shatsky et
al showed that HRG was capable of suppressing T cell proliferation (Shatsky et al., 1989). In
addition, Brown et al. also showed that HRG inhibits proliferating fibroblasts by interacting with
cell surface heparan sulfate and subsequently inhibiting the binding of acidic and basic FGF to
these cells (Brown and Parish, 1994). ´us, HRG has been reported to both inhibit and enhance
cell proliferation.
Chang et al reported that long-term treatment of peritoneal macrophages with physiological
concentrations of HRG results in the loss of cell adherence, probably mediated by a reduced
synthesis of cell surface adhesive proteins (Chang et al., 1992b). Olsen et al. found that HRG
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inhibits the adhesion properties of murine T–cell lines to plastic culture dishes, but that HRG
promoted homotypic adhesion between the cells (Olsen et al., 1996). In contrast, Lamb-Wharton
et al. found that HRG promotes T-cell adhesion, whilst also inducing a change in morphology
(Lamb-Wharton andMorgan, 1993).
Taken together, these results suggest that HRGmay be involved in regulating early adhesion
events of T- lymphocytes during immune responses at sites of inflammation.
1.1.4.5 Modulator of immune system
It is well established that certain autoimmune diseases, such as systemic lupus erythematosus (SLE)
and rheumatoid arthritis (RA), are associatedwith the production of autoantibodies (Mountz et al.,
1994). Moreover, in vitro studies have shown that autoantibodies can be cross-linked with their
cognate antigens to form insoluble immune complexes (IIC) (Sittampalam andWilson, 1984),
which can precipitate in target tissues and lead to a lack of nutrient transport and in consequence
to tissue injury. Physiological concentrations of the N-terminal domain of HRG can inhibit the
first stage of the formation of IIC (Gorgani et al., 1997), suggesting that HRG may play a role
in regulating IIC formation in vivo. HRG probably inhibits IIC formation by preventing Fc-Fc
interactions and by masking epitopes on IgG recognized by rheumatoid factors (Gorgani et al.,
1999b). Although HRGwas also found to promote solubilization of already formed IIC, HRG
was more effective at inhibiting the formation of IIC. Hence, some evidence suggest that HRG
may play an important role in the formation, solubilization and subsequent clearance of IIC in
vivo (Jones et al., 2005).
Recently, Gorgani et al. demonstrated that HRG binds to DNA and Fcγ RI and potentiates
the ingestion of apoptotic cells by humanmonocyte derived macrophages (HMDM) (Gorgani
et al., 2002). ´is points to an important role of HRG in the efficient removal of apoptotic cells.
´is theory is supported by HRG levels being low in the sera of human SLE patients (EKO, 1983).
1.1.4.6 Regulator of angiogenesis
Angiogenesis, the development of new blood vessels, is necessary for a variety of normal physiolo-
gical processes as well as for the growth and proliferation of tumors. ´e identification of natural
modulators of angiogenesis is essential to the understanding of this complex process, and may
provide attractive targets for therapeutic intervention.
One modulator of angiogenesis is HRG that exhibits both enhancing and inhibitory effects.
HRG binds to thrombospondin (TSP-1) (Leung et al., 1984) and inhibits the antiangiogenic
effect of TSP-1 in in vitro assays of endothelial cell migration and tube formation, and in vivo in
corneal angiogenesis assays (Simantov et al., 2001). ´ese studies suggest that HRG can modulate
10
1.1 Histidine-rich glycoprotein (HRG)
the antiangiogenic activity of TSP-1, and identifies a potential mechanism of resistance to the
antiangiogenic effect of TSP-1. In contrast, Juarez et al. (Juarez et al., 2002) reported that the
Histidine/Proline-rich (HPR) domain within HRG induces the apoptosis of activated endothelial
cells leading to potent antiangiogenic effects. In addition, Olsson et al. (Olsson et al., 2004)
demonstrated that HRG inhibits tumor vascularization in vivo, thus providing proof of concept
that HRG is an inhibitor of angiogenesis. In conclusion, HRG regulates angiogenesis.
1.1.5 Clinical reports of HRG
It is known that HRG is one of the few plasma proteins which shows amarked reduction in plasma
levels (approximately 50 %) during the last trimester of pregnancy (Halbmayer et al., 1992). HRG
acts as a negative acute phase reactant whereby plasma levels are markedly reduced during the
acute nonspecific response to tissue injury (Saigo et al., 1990). Plasma levels of HRG have been
found to decrease during acute states of diseases such as advanced liver cirrhosis (Leebeek et al.,
1989), AIDS, renal diseases, asthma and pulmonary diseases (Morgan, 1986).
1.1.5.1 Congenital HRG deficiency
´ree cases of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia have
been reported. Two cases of them were reported in Japan called Tokushima 1 (Shigekiyo et al.,
1993) and Tokushima 2 (Shigekiyo et al., 2000), and one of them was reported in Spain (Souto
et al., 1996). All probands who suffered from thrombophilia are women and the HRG level of
plasma is 20–50 % of normal. ´ese three cases suggest that HRGmay play an antithrombotic
role. Shigekiyo et al. suggested that the HRG deficiency is caused by intracellular degradation of
the mutated protein with the single nucleotide substitution of Gly 85 to Glu in the first cystatin
like domain in Tokushima 1 (Shigekiyo et al., 1998) and the Cys 223 to Argmutation in the second
cystatin like domain in the case of Tokushima 2 (Shigekiyo et al., 2000).
1.1.5.2 Familial association of high levels of HRGwith thromboembolism
As a consequence of HRG binding reversibly to plasminogen, the concentration of free plasmino-
gen available for the process of fibrinolysis will be reduced and therefore HRG can be regarded as
an antifibrinolytic protein (Lijnen et al., 1980). ´us, high plasma concentrations of HRGmight
predispose to thromboembolic complications and indeed a number of patients with thrombo-
philia have been described who had a persistent, sometimes familial, increase in their plasma
HRG levels.
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Castaman et al. reported of two unrelated families in Italy with a history of thrombosis and
genetically transmitted high levels of HRG (Castaman et al., 1993). Engesser et al. also reported
of a familial elevation in HRG plasma concentrations in a family with thrombophilia in the
Netherland (Engesser et al., 1987). Elevated levels of histidine-rich glycoprotein were present in
four family members over two generations suggesting a hereditary disorder.
In support of an association between high levels of HRG and embolism is a case report of
a woman with recurrent retinal vein occlusion in conjunction with increased plasma levels of
HRG (Kuhli et al., 2003). ´e authors suggested to consider increased plasma levels of HRG in
the differential diagnosis of coagulation disorders in the absence of cardiovascular risk factors.
1.2 Blood coagulation and fibrinolysis
1.2.1 The coagulation cascade
´e blood coagulation cascade is initiated when subendothelial tissue factor is exposed to the
blood flow following either the damage or activation of the endothelium. ´is may occur as
a consequence of the perforation of the vessel wall or activation of endothelium by chemicals,
cytokines, or inflammatory processes. ´e tissue factor binds to a serine protease, factor VIIa,
which is already present in blood and forms the factor VIIa-tissue factor complex (extrinsic
factor Xase). ´is complex activates the zymogens factor IX and factor X.´e limited amount of
the serine protease factor Xa generates picomolar concentrations of thrombin, which partially
activates platelets and cleaves the procofactors factor V and factor VIII generating the active
cofactors-Va and factor VIIIa, respectively. Factor VIIIa and the serine protease, factor IXa, form
the intrinsic factor Xase complex on a membrane surface provided by platelets, microparticles and
endothelial and other cells and activates factor X at 50-100 fold higher rate than the factor VIIa-
tissue factor complex. Factor Xa and the cofactor, factor Va, form the prothrombinase complex on
the membrane surface, which is the primary activator of prothrombin. ´e thrombin produced
further amplifies its own generation by activating factor XI and completing the activation of
platelets and factor V and VIII. ´rombin also cleaves fibrinogen and factor XIII to form the
insoluble cross-linked fibrin clot (Butenas andMann, 2002).
1.2.2 The fibrinolytic system
Blood coagulation is a complex enzymatic event culminating in the formation of an insoluble-
protein called fibrin. Together with platelets, fibrin forms a hemostatic plug to prevent excessive
bleeding. Fibrin blood clots are ultimately dissolved in order to restore vascular patency. ´e
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Figure 1.6: Scheme of the coagulation cascade.
Blood coagulation is initiated by vascular injury and results in the explosive generation of thrombin
which clots blood. Coagulation factors are represented by their Roman numerals (a= activated). Co-
agulation factors that bind to HRG are depicted by blue background.
Abbreviations: HMWK= highmolecular weight kininogen, PK= prekallikrein, TF= tissue factor, TFPI=
tissue factor pathway inhibitor, PF= phospholipid, TM= thrombomodulin, PC= protein C, PCI= protein C
inhibitor, TI= trypsin inhibitor, M= α2-macroglobulin.
enzymes involved in this physiologically important process are part of the fibrinolytic system (see
figure 1.7 on the following page).
´e central component in the fibrinolytic system is the glycoprotein plasminogen, which is
produced by the liver and is present in plasma and most extravascular fluids. Plasminogen is a
precursor enzyme (zymogen) which, following partial cleavage by a plasminogen activator is con-
verted to its active and proteolytic form, plasmin. ´e generation of plasmin occurs preferentially
on the fibrin surface, which offers binding sites for plasminogen and its principle activator in
blood, tissue-type plasminogen activator (t-PA). ´e binding stimulates plasminogen activation,
but also localizes the action of plasmin to sites of fibrin formation which promotes efficient clot
lysis.
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Figure 1.7: Schematic illustration of physiologic fibrinolysis.
Plasminogen is the proenzyme of plasmin, whose primary target is the degradation of fibrin in the vas-
culature. t-PA is the principle activator of plasminogen in blood, while u-PA is the predominant activator
outside the bloodstream in the extracellular matrix. t-PA is produced by the vascular endothelial cells
and is released into the circulation after stimulation. Fibrin regulates its own destruction by providing
receptors or binding sites for plasminogen and t-PA, thus localizing the action of plasmin. The inhibition
of the system can occur at the level of plasminogen activation (PAI-1) or at the level of plasmin (plasmin
inhibitor). Free t-PA as well as complexed t-PA/PAI-1 is cleared from the circulation by receptors in the
liver. Abbreviation: t-PA= tissue-type plasminogen activator, PAI-1= plasminogen activator inhibitor 1,
FDP= fibrin degradation products.
1.2.3 Thrombophilia
Venous thrombosis is a serious medical problem that annually affects 1 in 1000 individuals,
causing considerable morbidity and death due to pulmonary embolism. ´e pathogenesis of
the disease is multifactorial and several circumstances as well as genetic risk factors have been
identified.
´rombophilia is the term used for familial or acquired defects of the hemostatic system
that increase the tendency to clot. ´e term encompasses a susceptibility to both venous and
arterial thrombosis although, in the majority of patients, venous thrombosis of lower limbs is the
predominant clinical problem. Deficiency of antithrombin, protein C, protein S, and inherited
resistance to activated proteinC (APC-resistance), are themost common known genetic causes for
thrombosis. Together, they constitute about 60-70%of cases diagnosed as inherited thrombophilia
and may present as predisposing factors in up to one third of all affected patients with thrombosis.
1.2.4 Platelet signaling
´e importance of platelets in the development of arterial thrombosis and cardiovascular disease
is well established. On the basis of mouse gene-knockout studies and platelets from patients with
various haemostatic disorders, the specific contribution ofmany receptors involved in haemostasis
and thrombosis has been well defined and mentioned in the following (see figure 1.8 on page 16).
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GPIb/V/IX binds vonWillebrand factor (vWf) which is expressed on the subendothelium and
on the surface of platelets. ´is receptor also potentiates platelet activation in response to low-
dose thrombin, and is important in mediating platelet adhesion and aggregation under high-
shear conditions. GPIIb-IIIa is fundamental for a range of platelet responses, including platelet
aggregation, spreading and clot retraction. GPIIb-IIIa bindsmultiple ligands, including fibrinogen,
vWf, polymerized fibrin, fibronectin, vitronectin and soluble CD40 ligands. GPIa-IIa and GPVI
are the two major receptors supporting platelet adhesion on collagen. ´e GPVI receptor is non-
covalently associated with the immunoreceptor tyrosine-based activating motif (ITAM)-bearing
receptor, FcRγ-chain. Analysis of mouse platelets lacking GPVI or FcRγ-chain have demonstrated
an important role for this receptor complex in supporting platelet adhesion and activation on
fibrillar collagens. Two metabotropic receptors for ADP have been identified: P2Y1 and P2Y2.
Each ADP receptor is linked to one or more different G-protein(s).
´rombin uses three agonist receptors on the surface of platelets. Two of the three are clas-
sical protease-activated receptors (PAR1 and PAR4), which are linked to Gi,q,12/13 and Gq, 12/13
respectively. ´e other thrombin receptor is GPIbα. Two TXA2 receptors have been identified,
TP-α and TP-β, each of which is linked to Gq and G12/13.
All of these receptors activate specific signaling cascades which are ultimately linked to the
signaling of calcium ions released from intracellular stores. All soluble agonist receptors utilize
G-protein-coupled receptors that induce the activation of one or more PLC-β isoforms. Adhe-
sion receptors typically utilize non-receptor tyrosine kinases that regulate cytosolic calcium flux
through regulation of PLC-γ isoforms.
Novel antithrombotic approaches are likely to evolve from an improved understanding of the
mechanisms regulating thrombus formation as mentioned above. To elucidate the physiological
function of HRG binding to platelets in the presence of zinc, we generated HRG-deficient mice
(Tsuchida-Straeten et al., 2005).
1.3 Aims of this study
Although numerous biological properties of HRG have been reported including modulation
of the immune, the vascular and the coagulation system in vitro, the physiological function of
HRG has not been established yet. To elucidate the function of HRG in vivo, the project of “HRG
knockout mice” has started between the group of Prof. Jahnen-Dechent (IZKF BIOMAT) and
Prof. Koide (Himeji Institute of Technology, present: University of Hyogo, Japan). In this thesis, I
describe the progress of this project as detailed in the following:
1. As a first step of this project, overlapping phage clones including mouse Hrg gene were
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of mouse platelets lacking GPVI or FcR γ-chain have demonstrated an important role for this receptor complex in supporting platelet
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TP-β, each of which is linked to Gq and G12/13. All of these receptors activate specific signalling cascades that are ultimately linked to
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activation of one or more PLC-β isoforms. Adhesion receptors typically utilize non-receptor tyrosine kinases that regulate cytosolic
calcium flux through regulation of PLC-γ isoforms. For clarity, the details of specific signalling events linked to individual receptors have
been omitted. Targeting signalling processes linked to the regulation of GPIIb–IIIa have the potential to produce a significant number of
novel antithrombotic approaches. GP, glycoprotein; ITAM, immunoreceptor tyrosine-based activating motif; PLC, phospholipase C;
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Figure 1.8: Potential antithrombotic targets (Jackson and Schoenwaelder, 2003).
Schematic representation of the m jor adhesion an agonist receptors o the surface of platelets.
Abbreviations, GP, glyc protei ; ITAM, immu oreceptor tyrosine-based activatingmotif; PLC, phosphol-
ipase C; TXA2, thrombox ne A2; TP, thromboxane/prostanoid receptors; vWf, vonWillebrand factor and
PAR, protease-activated receptors.
isolated by the group f Prof. Jahnen-Dechent. ´e isolat d phage clon s were provided by
Prof. Jahnen-Dechent, subcloned and a complete nucleotide sequence of 13,591 bases was
determined in Prof. Koide´s laboratory (Tsuchida, 2000). To analyze the 5-prime upstream
region of the mouseHrg gene, pPAC4 clone was isolated, subcloned and as a result of this
a 1,889 nucleotides sequence was determined. Taken together a total sequence of 15,480
-nucleotides of mouseHrg gene was determined.
2. Next, the gene targeting vectorwas constructed by replacing a 1.8-kbXbaI-BamHI fragment
containing exon I with a 1.8-kb neomycin cassette for positive selection of resistant clones.
´ree correctly targeted embryonic stem cell clones were identified among a total of 144
neomycin resistant clones. We generated mice lacking the translation start point of exon I
of theHrg gene, effectively resulting in a null mutantion (Hrg-/-).
3. Our main interest in this study was to elucidate the physiological function of HRG in
16
1.3 Aims of this study
vivo. Homozygous HRG-deficient mice were viable and fertile. ´e histological analysis of
organs revealed no gross differences between wild-type and HRG-deficient mice. Since
it is known that HRG binds to fibrinogen, plasminogen and heparin, it is thought that
HRG regulates blood coagulation and fibrinolysis. In addition, three cases of hereditary
histidine-rich glycoprotein deficiency with familial thrombophilia have been reported.
´e major aim of this study was to elucidate the role of HRG in blood coagulation and
fibrinolysis by characterizing the generatedHrg-/- mice.
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2 Materials andMethods
2.1 Cloning and sequencing of themouse Hrg gene
2.1.1 Mouse 129/SvJ genomic library (cloning and sequencing)
Part of the work was performed in Himeji Institute of Technology, Japan as described in my thesis
for master degree (Tsuchida, 2000). A mouse 129/SvJ gemonic library was screened with a 1.1kb
EcoRI fragment of rat HRG. ´e phage DNA was extracted with the plate lysate method and
digested with endonucleases. ´e identity of the gene was confirmed by restriction mapping,
southern hybridization probing with mouse HRG cDNAs. Various restriction endonucleases
were obtained from Takara Shuzo (Kyoto, Japan), Toyobo (Osaka, Japan), Boehringer Mannheim
(Mannheim, Germany), MBI Fermentas (Lithuania), or New England Biolabs (Beverly, MA,
USA).´e nucleotide sequence was determined by the dideoxy chain termination method with
´ermo Sequenase Cycle Sequencing Kit (Amersham Pharmacia Biotech, England) and a DNA
Sequencer, DSQ-1000L (Shimadzu, Japan). Repeat sequences were analyzed at the RepeatMasker
WebServer (http://p.genome.Washington.edu/cgi-bin/RepeatMasker).
2.1.2 Mouse RPCI21 genomic library
2.1.2.1 Isolation of pPAC4 DNA
To determine the nucleotide sequence of further upstream regions of the mouse Hrg gene, a
mouse RPCI21 genomic library inserted to pPAC4 vectors was screened with a 303-bp fragment,
which was amplified with a forward primer: 5’-CCATGCAGCAGTGAGGAGAAAAC-3’ and a
reverse primer: 5’-CATGCAGAGTAACTGGTACCACT-3’ located at position -1741 to -1439 in
figure 3.5 on page 36. ´e screening was performed at the RZPD (Deutsches Ressourcenzentrum
für Genomforschung GmbH) and the clone RPCIP711L09236Q2 was obtained. ´is pPAC4
clone was cultured under the condition of kanamycin resistance. ´eDNAwas isolated according
to the QIAGEN plasmid protocol “isolation of BAC DNA” (QIAGEN GmbH, Hilden, Germany).
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2.1.2.2 Southern-Hybridization analysis of the pPAC4 clone DNA
To confirm if the mouseHrg gene is contained in the pPAC4 DNA, the DNA was digested with
restriction endonucleases (see figure 3.1 on page 30 and figure 3.2 on page 31). ´e gel was
transferred to a Nytran Plus membrane (Schleicher & Schuell, Dassel, Germany) and hybridized
with the same 303-bp fragment as used for the screening at 42°C overnight. ´e DNA probe was
labeled with α32P-dCTP (HARTMANNANALYTiC GmbH, Braunschweig, Germany) before
hybridization and was purified with a G-25 spin column (QIAGENGmbH, Hilden, Germany).
´emembrane was washed at room temperature for 5 minutes with buffer 1 (2×SSC, 0.1 % SDS)
once and washed at 45°C for 15minutes with buffer 2 (0.5 % ×SSC, 0.1 % SDS) twice and analyzed
by autoradiography.
2.1.2.3 Subcloning and sequence determination of themouse Hrg gene
To determine the nucleotide sequence of further upstream regions of the mouse Hrg gene, a
HindIII 4.6-kb fragment of the pPAC4 clone DNA was isolated by the shot gun cloning method
and screened by the colony hybridization method. Briefly, pPAC4 clone DNA was digested with
HindIII, ligated with pUC18HindIII cut vector at 37°C for 1 hour and transformed. Colonies
on agar plates were tranferred to S&SMembranes (Schleicher &Schuell, Dassel, Germany) and
hybridized with a 303-bp fragment as shown in figure 3.3 on page 32. ´e method is described in
detail in the manuscript of Colony and Plaque lis onto S&S membrane (Schleicher &Schuell,
Dassel, Germany). Aer the confirmation of theHindIII 4.6-kb fragment with various restric-
tion endonuclease digestions, it was subcloned and the nucleotide sequence was determined by
Sequencer and analyzed with the Sequencher™ soware.
2.2 Gene targeting
2.2.1 Construction of the gene targeting vector
A replacement vector was constructed according to the methods used in the fetuin-A knockout
(Jahnen-Dechent et al., 1997). ´e length of PGKNeo vector is 8910 bp nucleotides. ´e vector
consists of four regions, 2110 bp of pMC/TK (thymidin kinase), 1830 bp of pGKNEO (neomycin
cassette), 2830 bp of pGK/TK (thymidin kinase) and 2080 bp of pBR322 (backbone sequence). A
1.9-kb SalI-XbaI fragment of the mouseHrg gene including a part of exon I was inserted as 5’
homology region into the polylinker site 1 of pGKNeo vector, whichwas opened byXhoI andAvrII
digestion. A 7.8-kb BamHI genomic fragment of the mouseHrg gene, which contains exons II to
VII, was filled with dGTP and dATP in the BamHI site. ´is fragment was inserted as 3’ homology
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region into the polylinker site 2 of pGKNeo vector, which was predigested with SalI and filled
with dCTP and dTTP. Ligation was always performed at 16°C overnight. ´e competent cells,
DH5α were transformed with ligated DNA according to the manuscript of Invitrogen (Invitrogen
GmbH, Karlsruhe, Germany).
´us, the targeting vector was constructed by replacing a 1.8-kb XbaI-BamHI fragment
containing exon I with a 1.8-kb neomycin cassette.
2.2.2 Establishment of a southern strategy
For the screening of positive ES cells generated by homologous recombination and for the geno-
typing of the mice, it was essential to establish a southern strategy. At first, four kinds of DNA
fragments were tested as probe candidates for southern-blot analysis. ´ese probe fragments
were isolated from PAC clone DNA located upstream from the 5’ homology sequence that had
been inserted into the gene targeting vector (see figure 3.10 on page 41). To exclude unspecific
binding because of repetitive sequences in the potential probes, these probes were electrophoresed
on a 1.0 % agarose gel and blotted onto Nytran plus membrane (Schleicher & Schuell, Dassel,
Germany) overnight. ´is membrane was hybridized with mouse genomic DNA probe. ´e
DNA probe was labeled with α32P-dCTP before hybridization according to the manuscript of
DECAprime™II (Ambion Inc, Texas, USA).Hybridizationwas performed in the PerfectHyb™PLUS
hybridization buffer (Sigma, Steinheim, Germany) at 42°C overnight. ´emembrane was washed
once with buffer 1 (2×SSC, 0.1 % SDS) at room temprature for 5 minutes and washed twice with
buffer 2 (0.5 % ×SSC, 0.1 % SDS) at 68 °C for 15 minutes and analyzed by autoradiography (see
figure 3.11 A on page 42). Next, genomic DNA extracted from wild-type mouse tail tips was
digested withHindIII and ScaI at 37°Covernight. ´e digestedDNAwas electrophoresed on 0.7 %
agarose gels and blotted on to Nytran plus membranes (Schleicher &Schuell, Dassel, Germany)
overnight. ´e membranes were hybridized with a SmaI 0.6-kb and a PstI/BglII-0.6 kb probe.
Since 4.6-kb and 10.4-kb fragments were detected by the SmaI-0.6 kb probe aerHindIII and
ScaI digestion respectively, this probe located at –3107 to –3678 in the sequence of figure 3.5 on
page 36 was determined to be appropriate as southern-probe.
2.2.3 Gene Targeting in ES Cells
Dr. Silke Ensslen and Dr. Markus Moser performed the following procedures: 129/Ola em-
bryonic stem cells (passage 10) were grown on a mouse embryonic fibroblast feeder layer and
electroporated with 60 µg of PvuI-linearizedHrg-neo replacement vector DNA following estab-
lished protocols by Nagy A, 1993. Aer positive-negative selection using G418 (400 µg/ml final
concentration) and ganciclovir (2 µM final concentration), 144 resistant clones were isolated,
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cryo-conserved and replicas were used for DNA preparation. To extract genomic DNA proteinase
K buffer for ES cell was prepared as follows:
Proteinase K buffer for ES cells: 100 mM Tris-HCl pH 8.5
5 mM EDTA
0.2 % SDS
200 mM NaCl
100 µg/ml Proteinase K
Aer washing the ES cells with PBS, 500 µl of proteinase K buffer for ES cells was added to each
well and the plate was incubated at 37°C for 3 hours. 500 µl isopropanol was mixed to each well
and the plate was gently stirred for 1 hour at 4°C. ´en the genomic DNA was picked up and
transferred to a tube which contains 500 µl 70 % ethanol. ´e tube was centrifuged at 3000 g for
10minutes, the 70 % ethanol was discarded and the pellet was dried at 60°C for 30minutes. 200 µl
TE buffer (10 mM Tris-HCl pH8.0, 1 mM EDTA) was added to the tube and incubated overnight
at 4°C.
2.2.4 DNA Analysis
DNA from individual ES cell clones was digested with ScaI orHindIII, separated by 0.7 % agarose
gel electrophoresis, and transferred to nylon membrane. Blots were probed with the 0.6-kb
SmaI fragment located immediately upstream of the 1.9-kb SalI-XbaI fragment contained in the
replacement vector. ´is probe detects a 10.4-kb ScaI fragment or a 4.6-kbHindIII fragment in
wild-type DNA and a 6.5-kb ScaI fragment or a 8.4-kbHindIII fragment in the correctly targeted
allele (see figure 3.9 on page 40).
2.2.5 Blastocyst Injections
Blastocysts were harvested 3.5-day post-coitum from naturally mated C57BL/6 mice. About 15
ES cells were injected into each blastocoele, and blastocysts were implanted into the uterine horns
of pseudopregnant C57BL/6 X CBA F1 hybrid mice. Two independent ES cell clones (clone 33
and clone 24) yielded fertile chimeras upon blastocyst injection. ´e injection was performed by
Dr. Silke Ensslen. One clone 33 chimeric female and one clone 24 chimeric male transmitted the
targetedHrg locus through the germline as demonstrated by Southern blot analysis of tail DNA
from F1 offspring.
22
2.2 Gene targeting
2.2.6 Genotyping
To prepare the genomic DNA of mouse tail, proteinase K buffer was prepared as follows:
Proteinase K buffer (500 ml): 50 ml 1.0 M Tris pH 8.5
5 ml 0.5 M EDTA
10 m 10 % SDS
20 ml 5 M NaCl
415 ml dH2O
Proteinase K stock solution: 20 mg/ml in dH2O
500 µl proteinase K buffer with a final concentration of 100 µg/ml proteinase K was added to the
tube containing the mouse tail tip and was incubated overnight at 55°C.´e eppendorf tube was
centrifuged at 14000 rpm for 10 minutes and the supernatant was transferred into a new tube
containing 500 µl isopropanol. ´e genomic DNAwas picked up and transferred into 250 µl 70 %
ethanol. Aer vortexing, the tube was centrifuged at 14000 rpm for 1 minute and the supernatant
was discarded. ´e pellet was dried at 55°C for 1 hour and 180 µl TE buffer (10mMTris, 1mM
EDTA, pH 8.0) was added to the pellet.
Genotypes were determined by either PCR or southern blot analysis. PCR analysis was
carried out using the following primers: P1 (5’-TTGAATGATTCT AATGTGAAGGC-3’) as
forward primer which is located immediately upstream of the segment used for the targeting
vector construction and P2 (5’-GGTCCTCATTTCCGCATTCCGTGGA-3’) as reverse primer
which is located within the deleted region of the Hrg gene to detect the wild-type allele. P3
(5’-TTGTGTAGCGCAAG TGCCAGCG-3’) is also a reverse primer located in the neomycin
cassette. PCR with P1 and P2 generates a 3091-bp product from the normal allele, while P1 and
P3 amplify a 2077-bp region of the targeted allele (see figure 3.9 on page 40). Oligonucleotide
primers were synthesized in MWG-Biotech AG (Ebersberg, Germany).
Protocol of polymerase chain reaction (PCR) of genotyping
PCR mix: 2 µl Genomic DNA (template)
5 µl 10×PCR buffer
1 µl 10 (pmol/µl)Primer 1
1 µl 10 (pmol/µl)Primer 2
1 µl 10 (pmol/µl)Primer 3
1 µl 10 mM dNTP (final conc. 0.2 mM each)
1 µl 1M Betain (final conc. 20 mM)
0.2 µl Taq polymerase (final conc. 0.04U/µl)
0.02 µl Pwo DNA polymerase (final conc. 0.004U/µl)
37.8 µl H2O
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Reaction cycles: 2 min 68°C Ô˙ add template DNA
1 min 94°C
10 sec 94°C
1 min 55°C
8 min 68°C
ŔŤŤŤŤŤŤŤŤŞŤŤŤŤŤŤŤŤŚ
– 10 cycles
1 min 55°C
8 min 68°C
24 min 68°C
ŔŤŤŤŤŤŞŤŤŤŤŤŚ – 30 cycles
For Southern blot hybridization analysis, genomic DNA was digested withHindIII or ScaI, separ-
ated electrophoretically, blotted onto nylon membrane (Schleicher & Schuell), and hybridized
with a 32P-radiolabeled 0.6-kb SmaI probe as described in section 2.2.2 on page 21.
2.3 Analysis of HRG-deficient mice
2.3.1 Immunoblot analysis
Immunoblot analysis was performed as described by Jahnen-Dechent et al. (Jahnen-Dechent
et al., 1994). Briefly, a sample of 0.2 µl serum was separated by SDS-PAGE using mini gels (8 X 5
X 0.075 cm). Proteins were electrotransferred onto nitrocellulose membrane (Optitran BA-S83,
Schleicher & Schuell, Dassel, Germany) and the transfer was checked by staining with PonceauS
red stain. Immunoblots were saturated in blocking buffer (20mM TRIS/HCl, pH 7.8, 0.15 M
NaCl) containing 0.02%Tween 20 and 5%drymilk powder as blocking reagents. To detect bound
HRG we used rabbit antiserum raised against human HRG, which cross-reacts with mouse HRG,
peroxidase-labelled secondary antibody and the enhanced chemiluminescence reagent kit (ECL
reagent, Amersham-Pharmacia, Freiburg, Germany) following the manufacturer’s instructions
and our own published protocols (Schinke et al., 1997).
2.3.2 Hematological analysis
Blood samples were collected by cardiac puncture and serum was obtained by centrifugation
at 1,500 X g for 15 min. Serum chemistry was performed using a Vitros 250 analyzer (Ortho-
chemical Diagnostics, Necher Giemlind, Germany). EDTA-blood samples were used to carry
out hemograms using a Celltek-M analyzer (Nihon Khoden; Johnson & Johnson, Bad Hamburg,
Germany). For coagulation assays blood was collected by cardiac puncture and immediately
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mixed with sodium citrate (9:1 vol/vol with 3.8 % sodium citrate). Mouse platelet-poor plasma
was obtained by centrifugation of citrated blood at 1,500 X g for 15 min.
Antithrombin activity was determined using the COAMATIC® Antithrombin kit (Chro-
mogenix, Orangeburg, NY, USA) and control plasma N (Dade Behring, Marburg, Germany) as
standard according to the manufacturer’s instruction. Fibrinogen was determined according to
the method of Clauss (Clauss, 1957) using a commercial kit (Sigma, Taufkirchen, Germany, pro-
cedure No 886). Prothrombin time (PT) was measured using a KC10A coagulometer (Heinrich
Amelung GmbH, Lemgo, Germany). ´romboMax reagent with calcium was obtained from
Sigma (Taufkirchen, Germany) for clotting assays. HumanHRGwas purified from human plasma
and was kindly provided by Prof. Koide.
2.3.3 Platelet aggregation analysis
Blood was collected by cardiac puncture and was anticoagulated with sodium citrate (1 vol 3.8 %
citrate/ 9 vol blood). Platelet-rich plasma was prepared as follows. Citrated blood was centrifuged
at 1800 rpm for 5 minutes and the supernatant including erythrocytes was taken. ´e supernatant
was further centrifuged at 800 rpm for 6 minutes to obtain platelet-rich plasma (PRP). To obtain
platelet-poor plasma (PPP), the supernatant was additionally centrifuged at 3000 g for 10 minutes.
PRP and PPP were pooled from 4-6 mice. Platelet count was adjusted to 350×103/µL with PPP or
Tyrode’s buffer. For some experiments washed platelets obtained from PRP were used. For this
purposes platelet-rich plasma was centrifuged at 2800 rpm for 5 min at room temperature and
the pellet was resuspended in 1 ml Tyrode’s buffer.
Tyrode’s buffer (100ml): 5 ml Stock solutionI (2.73 M NaCl, 53.6 mM KCL,
238 mM NaHCO3, 8.6 mM NaH2PO4)
2 ml 0.1M CaCl2
1 ml 0.1MMgCl2
1 ml 0.5M Hepes
3.6 ml 10% BSA
1 ml 10% Glucose
86.4 ml H2O (Part of the H2O should be added before
pipetting the stock solutions.)
ph 7.35 (with HCL)
Aer incubating the resuspended platelets in Tyrode’s buffer for 10 minutes at 37°C the procedure
of centrifugation, resuspension and incubation was repeated once. ´ereaer a further centrifu-
gation step was carried out and the pellet was resuspended in 450 µl Tyrode’s buffer. ´e platelets
were incubated at 37°C for 30 minutes before use. ´is protocol of platelet preparation was
kindly provided by Dr. Tamer Rabie, University of Würzburg, Germany. Platelets were stimulated
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with 20 µM ADP, 10-20µg/ml collagen and 0.15U bovine thrombin. ADP and collagen were
obtained from AMAX (Wicklow, Ireland). Platelet aggregation activity was measured in a platelet
aggregometer (Labor FIBRINTIMER® , Ahrensburg, Germany).
2.3.4 Whole blood clot lysis
Dilutedwhole blood clot lysis was determined as follows: 100 µl fresh blood, collected by vena cava
puncture was diluted 10-fold with 0.9 % saline containing ˆ10,000 cpm human 125I-fibrinogen
(0.01µCi 125I, Amersham, Buckinghamshire, United Kingdom) and was coagulated at 37°C with
8 µl bovine thrombin (75 U/ml, Sigma, Taufkirchen, Germany), and 10 µl 0.75 M CaCl2 solution.
At various time points, the 125I- fibrinogen content of 50 µl supernatant aliquots was measured
using a LB 951G gamma counter (Berthold, Technologies, Germany).
2.3.5 NuPAGETM electrophoresis analysis
´e release of 125I- labeled fibrin degradation peptides was analyzed by NuPAGE™ electrophoresis.
NuPAGE electrophoresis was performed according to the manufacture’s instruction using a
commercial kit (NOVEX Electrophoresis GmbH, Frankfurt, Germany). ´e release of 125I-
labeled fibrin degradation peptides was analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) using 10 µl of reduced lyzed clot supernatant and 10 % Bis-Tris Gels.
´e gel was stained with coomassie solution, dried and exposed to X-ray film for 2 days at -80°C
and developed.
2.3.6 Bleeding time
´e tails of 2–4 month-old anesthetized mice (100 mg Ketamine and 5 mg Xylazine per Kg
intraperitoneally) were prewarmed for 5 min at 37°C in a water bath and a 5 mm segment of
tail tip was amputated with a razor blade. ´e tail was immersed immediately in 10 ml 37°C
prewarmed saline, and the time was taken until the bleeding stopped.
2.3.7 Induction of skin wounds
Mice were anesthetized, shaved dorsolaterally and swabbed with 70 % ethanol. A full thickness
wound was inflicted using an 8-mm dermal biopsy punch. Wound areas were photographed daily
and the wound area was measured histomorphometrically using National Institutes of Health
IMAGE soware.
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2.3.8 Immunoblot analysis of platelet HRG
Platelets (175×104) of platelet-rich plasma (PRP) from wild-type and HRG-deficient mice were
washed twice using Tyrode’s buffer. ´en washed platelets were resuspended with 100 µL resus-
pension buffer (containing 15 mM Tris-HCl, pH 7.6, 0.14 M NaCl and 5 mM glucose). 10 µL
platelet proteins of 175×103 platelets were reduced with β-mercaptoethanol in sample loading
buffer for SDS-PAGE and the HRG protein was detected aer western blotting by immunological
staining using a rabbit polyclonal antibody raised against human HRG (usually diluted 1: 5000),
peroxidase-labeled secondary antibody (usually diluted 1:10000) and enhanced chemilumines-
cence detection.
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3.1 Cloning and sequencing of themouse Hrg gene
3.1.1 Characterization of the upstream region of themouse Hrg gene
To determine the nucleotide sequence of a further upstream region of the already determined
mouseHrg gene sequence (GenBank No. AB055898), a mouse RPCI21 genomic library inserted
into pPAC4 vector was screened with a 303-bp mouseHrg gene fragment isolated from -1741 to
-1439 (see figure 3.5 on page 36) by RZPD Deutsches Ressourcenzentrum für Genomforschung
GmbH (Berlin, Germany), and one positive clone RPCIP711L09236Q2 was obtained. To confirm
if this clone contained the mouseHrg gene, southern-hybridization analysis was performed with
the 303-bp probe which was used for screening of the PRCI21 genomic library.
´e digestion of the pPAC4 DNAwith a series of restriction enzymes in single and double
digestion mixes revealed very different restriction patterns for the enzymes (figure 3.1 on the
next page and figure 3.2 on page 31). Some rare cutting enzyme including ClaI, FseI and NotI
(figure 3.1 B lane 1,3 and 6, figure 3.1 D, lane 1,4 and 10) as well as SalI (figure 3.2 D lane 1,4 and
10) generated large restriction fragments (> 20 kb) which were detected by the 303-bp probe. On
the other hand the probe detected only short fragments of < 4 kb aer digestion with EcoRI or
BamHI (figure 3.2 B).
Based on the results of the restriction enzyme digest analysis shown in figure 3.1 and figure 3.2,
a restriction enzyme map was created (figure 3.3 on page 32). While the prior in GenBank
published mouseHrg sequence (No. AB055898) was determined only up position –1789, the
characterization of the genomic Hrg gene sequence inserted in the pPAC4 vector revealed an
upstream region ranging up to –19,400. ´erefore, we determined the sequence ofHindIII 4.6-kb
fragment that contains the upstream region of translation start codon.
3.1.2 Subcloning and sequencing of the upstream region of themouse Hrg gene
From the restriction enzymemapof the upstream region of themouseHrg gene shown in figure 3.3
on page 32 one restriction fragment was chosen for subcloning and subsequent sequencing. ´e
4.6-kbHindIII fragment was chosen for this purpose because it covered a sufficient part of the
already sequenced region to be sure of the right orientation. In addition it contained an unknown
29
3 Results
? ?? ????? ? ?? ??? ?
?? ????? ? ?? ??
????
???
???
???
????
????
???
???
???
???? ?? ?? ??
? ? ? ??
??? ? ?
?
? ?
? ?? ????? ? ??? ?
????
???
???
???
????
? ?? ????? ? ??
????
???
???
???
???? ???? ???? ????
?? ?? ?? ???? ??
? ?? ?? ??
?
?
Figure 3.1: Restriction enzyme digestion and southern-hybridization analysis of the pPAC4 clone
PRCIP711L0936Q2.
(A) The pPAC4 DNAwas digested with various restriction enzymes and separated by agarose gel (0.6 %)
electrophoresis. The enzymes used were ClaI (lane 1), Cla/EcoRV (lane 2), ClaI/FseI (lane 3), ClaI/NheI
(lane 4), ClaI/ScaI (lane 5), ClaI/NotI (lane 6), EcoRV (lane 7), EcoRV/FseI (lane 8), EcoRV/NheI (lane 9),
EcoRV/ScaI (lane 10) and EcoRV/NotI (lane 11). As DNA standard a λDNAHindIII ladder was used (M).
(B) Southern blot analysis of the pPAC4 clone DNA digested with the restriction enzymes as noted in (A).
(C) The pPAC4 clone DNA was digested with an additional set of restriction enzymes: FseI (lane 1),
FseI/NheI (lane 2), FseI/ScaI (lane 3), FseI/NotI (lane 4), NheI (lane 5), NheI/ScaI (lane 6), NheI/NotI (lane
7), ScaI (lane 8), ScaI/NotI (lane 9) and NotI (lane 10).
(D) Southern blot analysis of the pPAC4 clone DNA digestedwith the restriction enzymes as noted in
(C). For both southern blot analysis the digested DNAwas transferred to a positively- charged nylon
membrane after gel electrophoresis and was hybridized with the 303-bp fragment as used before in the
screening. The sizes of the different fragments detected by the probe are indicated in (B) and (D).
upstream portion which was large enough to be of interest but still easy to handle. ´eHindIII 4.6-
kb fragment was subcloned into a pUC18 vector and as a result of this further 1,889 nucleotides
sequence was determined.
Figure 3.4 onpage 33 shows the sequencing steps of the upstream region of themouseHrg gene.
´e directions and extents of the individual sequencing reactions are summarized in figure 3.4
together with a partial restricition map of the subclonedHindIII 4.6-kb fragment. ´is fragment
contains SmaI 0.6-kb, SmaI/StuI 0.7-kb, PstI 0.8-kb, SacI/KpnI 1.0-kb, StuI 1.3-kb and SpeI/AvrII
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Figure 3.2: Restriction enzyme digestion and southern-hybridization analysis of the pPAC4 clone
PRCIP711L0936Q2.
(A) The pPAC4 DNAwas digested with various restriction enzymes and separated by agarose gel (0.6 %)
electrophoresis. The enzymes used were EcoRI (lane 1), EcoRI/BamHI (lane 2), EcoRI/SalI (lane 3),
EcoRI/HindIII (lane 4), EcoRI/SacI (lane 5), EcoRI/NotI (lane 6), BamHI (lane 7), BamHI/SalI (lane 8),
BamHI/HindIII (lane 9), BamHI/SacI (lane 10) and BamHI/NotI (lane 11). As DNA standard a λ DNA
HindIII ladder was used (M).
(B) Southern blot analysis of the pPAC4 clone DNA digested with the restriction enzymes as noted in (C).
(C) The pPAC4 clone DNA was digested with an additional set of restriction enzymes: SalI (lane 1),
SalI/SacI (lane 2), SalI/HindIII (lane 3), SalII/NotI (lane 4), HindII (lane 5), HindIII/SacI (lane 6), HindIII/NotI
(lane 7), SacI (lane 8), SacI/NotI (lane 9) and NotI (lane 10).
(D) Southern blot analysis of the pPAC4 clone DNA digestedwith the restriction enzymes as noted in
(C). For both southern blot analysis the digested DNAwas transferred to a positively- charged nylon
membrane after gel electrophoresis and was hybridized with the 303-bp fragment as used before in the
screening. The sizes of the different fragments detected by the probe are indicated in (B) and (D).
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Figure 3.3: Restriction enzymemap of themouse Hrg gene resulting from southern blot analysis.
Themouse Hrg gene 5’ probe, 303-bp fragment isolated from -1741 to -1439 as shown in figure 3.5 on
page 36, is shown as red square at the top together with the complete restriction map. Beneath the
map the length and position of the single fragments obtained after individual digestions which were
detected by the 5’ prime probe are indicated as black arrows. The HindIII 4.6-kb fragment subcloned
into pUC18 is shown as red arrow.
0.5-kb fragments. Various DNA fragments obtained by restriction endonuclease digestions were
subcloned into a pUC18 vector. ´e nucleotide sequence of each fragments was completely
determined in both directions, which resulted in further upstream of 1,889 nucleotides sequence
was determined.
3.1.3 Structural characterization and nucleotide sequence of mouse Hrg gene
Figure 3.5 on page 36 shows the structure of the mouseHrg gene locus including exon and introns
as well as a partial restriction map. ´e complete nucleotide sequence of 13,591 bases (AB055898)
was determined by sequencing two overlapping lambda EMBL3mouse genomic DNA clones. An
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Figure 3.4: The sequencing strategy of the upstream region of themouse Hrg gene.
The directions and extents of the sequencings derived from the individual subcloned restriction frag-
ments are indicated by black arrows. A partial restriction map is shown at the top. The sequence
attained from themouse genomic library 129/SvJ, which was deposited in the database (GenBank No.
AB055898), is shown as red arrow. The sequence of the upstream region of themouse Hrg gene derived
from themouse genomic library RPCI21 is shown as blue arrow.
additional upstream sequence was determined from an overlapping clone isolated from a RPCI21
library which additionally yielded 1,889 nucleotides. A total sequence of 15,480-nucleotide
is shown in figure 3.5 on page 36. ´e alignment with the cDNA sequence in capital letters
demonstrates that the gene for mouseHrg is composed of six small exons, exon I through VI (81
to 225 bp), and one large exon, exonVII (905 bp). ´e size of introns varies from 677 bp to 2315
bp. ´is exon-intron structure was very similar to that of the human gene (Wakabayashi et al.,
1999) where seven exons were likewise identified. ´e structural organization into two groups
of three exons coding for a cystatin-like protein domain each, and one additional larger exon
coding for a third protein domain specific of the respective protein is also present in the related
fetuin family proteins, Ahsg (Jahnen-Dechent et al., 1997) and FETUB (Denecke et al., 2003). ´e
inspection of the genomic loci of these proteins revealed that they are next neighbours on mouse
chromosome 16 and therefore probably originated by gene duplication. A similar arrangement is
conserved in the human genome on chromosome 3 (Ensembl Gene: ENSG00000113905).
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gtgcc-3678 gtaagcttga gcaatagcat tttgaaaaca ttaataacaa caagagttaa caatagtgca ttggtgttcc attaagggca -3601
gaaatcaaag ccttggagtt taaccaagag tgagttcaga tttgaatgac ctactgtgct ttctctgtgt cttccgtcag ccctgtctgt atgccatgtg -3501
agtctgaatc catgcctgct taaaggctgt catataaatc tgtctgtctc catctctctg tgtgtcccta actaggagct tctgttttga atttattgaa
gagtacgaaa acatcacatt agcaaagaag aaggaattct ttagagaaat ctttaacaga gtttgacaag gactaagtca cagactccaa ctgattcaga
aaacaaacag tattacaaca tcattgtttc tcaagcatta tctgtgtgtt gtatatattt atggtggatg acataagggt gtttccaacc tacaaacaca
catgctttac tcatgggcca ggggcatgag gagtatatac gtgaggataa cagccgcgca ttagcttagg ttgtaaaagt tgatttcacc cgggcagtag
tggcacacac ctttaattcc agcacttggg aggcagaggc aggtgaatct ctgagttcca tgatagccag aatgcaacca accaaccaac caacaaacaa -3001
acagttgact tcttacacag agaaaccctg tttccaaaca aacaaagcaa aacaaaacaa aacaaaatgt tgatttcatg ggaaatccaa ggcaaataag
tgtgactgtt acactgtcct cttaaaagca cattaaataa acaggctgaa tacaagtagg agagcagtct taggtcttaa ggtactacaa agtttattac
taaccctggc tgtgaggctc agcaggagtt caagtgtctt agcatggaag agatattttt tctttttaaa atttatttat ttatttattt attcattcag
tttatatcct gatcactgcc ctcttcttcc cagtcttccc cttagatgcc ccacgccccg ccaaagtatc cctgatatat aaagtctctg caggcaggtg
catcctcttt caccgaagcc aaacaaggca tcccagttat aagaatgaag agccacaggc aggcaacagg tttcaggaca gcccctgctc cagttgttgg -2501
ggatctgcat gaagaacatg ctgctcatct gatgcatatg tgcaggaggc ctaggtccag tccgtgtatg ttctttggtt ggtgattcag tctctgagag
ctcctaaggt ccaggtgagt tgactctgtt ggtcttcctg taaagttcct atcccctcca gggccctcaa tccttccccc aactcttcca taagactccc
tgagctctgt ccagtgtttg ctgtgggtct tgatgcgtct gttacagtcc gctgctgggt ggagtctctc agaggaaagc catgctaggc tcctgtgtgc
aagtttaaca gagcatcact actagtgtca gggattggtg cttgcccatg gcatgggtcg agatattatc ataatactgc attgccactt atagactcca
taatgtgtct gtcttagttt cttttgtatc ttcttcacca tacaaaagcc cagtccttct cagccttgac aacactgaaa tgatctggaa tttgaaaact -2001
gcctttgctt ggatctacca ctaattctaa ctgaaaagat ctggacacct gcagtgatag ttttccttct ggatgtgaaa ctcaggactt tgtgcatgct
tggcaagagt ctaccaccaa gaagcacctc cagtccaaca ccaggatttt tcttaaagtt ctttgaatga ttctaatgtg aaggcaaggt tactcatcat
tgctgcagat cttcactgta gagaaagttc aggaagaggg gagatgctgt agtgacactc catgcagcag tgaggagaaa acctaggcag gatttcttgg
gttccttctg aaactgcagc ctctacaagc atggaggctc cacactatgg aggggttgga taagggctgc tgtattcaac cctgttccca gtgacaagcc
cttccccaaa tgagatagtc actcaatttc tcagtcccta tctgtctcac cagtgtcttc ttttgtatga tttgctttaa gggccacaag taacgaggat -1501
ggcatgggag gacccctagt tatagcacaa acactaataa gtggtaccag ttactctgca tgtatgctgt gcccaagact ggaccgactg acatagacat
ggcttcttat tcattgcatg gcattgccaa gaactatcaa ttcacatttc ataaataaaa aacctaagag tcaaaggatg tggtggtttg aataagaatg
cccccccccc cccgccgtgc tggatagtat gtcaacctga cacaagctaa agttatctta gaggagggaa cctccattaa gaaaatgcct ccataagatt
gggttatagg caggccttta gagtattttc ttaattagtg attgatgggg acaggcccag cctattggtg gggccactcc ccaataggtt ctataagaaa
gcagactgag caagccataa ggagcaagca agtaagcagc acttatcgag ggtctctgta tcaacgccca cctccagttc cttgtgctga tggcctgtcc -1001
cgacttcctt caatgatgac tgttgatata gaaatatgag gcaaataaac cctctcctcc ccaagttgct tttggtcatg gtgttccatc atgacaatag
gagcttaatt aagacatccc cacataggct tatatgtgtc ggaatgcgta ggcatagaga atggcactac ttgagaagaa ttaagaggtg tggccttgtt
ggagtgaatg tggccttgtt agaggaaatg tgtcactcag ggtgggcttt gaagtttcaa aaggccaagc caggcccagt ggcttctgcc tgtggatcca
gatgtaaaac ttgtagcgat atccaatacc atgtctgtct ttgcatgcca ccatgcttcc cacaatgatg ataagggact aaacctctaa aactgaaagc
aagctccaat gaaatgcttt ctttgataag agttgccatg gtcatggtgt cgcttcacag caatagaaca gtgactaagg cagaggggtt ctaaagcatt -501
acacagtaat aagataacag tgtcaaatgt ccatctgatt ccacagtcac agctgaaggc caggcccttc aagaggcagg ctgtgggatg ggttacctgc
ctcagataat tttcctgtgt ttggctaagg aattttagcg ccataatcca aagatgcagc tgacaataga gatttccaaa tgagacagct ataagaaaac
ttattcccaa ctccaccata acaacacaat aagtgctttg ggttaaacac accctgaatc agttacccac cagatatagc atattgcaca aatgatgatt
ttacccactc attggtgtta tgtctcaact ttctctacac taattattta cagactgttg acagatattt gaacctgggg tcaaagtgaa catgcccagt
tatacaacaa aaaatctata aagaccttta tcaattgagt gtgcatcacg gtagaattCT CTCTGCTATG GTGGACCACA GTCAAGGATG GTTTAGCACA -1
ATGAAGGTGC TCACCACAGC ATTGCTTCTA GTCACCCTGC AGTGTTCCCA TGCCCTGAGT CCCACCAACT GTGATGCTTC TGAGCCTCTG GCTGAGAAAG 100
TTCTAGACCT GATCAATAAA GGGCGGAGGA GTGGCTATGT TTTCGAGCTG CTGCGGGTCT CTGACGCCCA CTTGGACAGA GCGgtaagac atggccaatg
gaggagttga gctgggagac aatgtggaag gtgggaaagg gattggagga gcagactgct ttgcgtaatt aacaaccttc atcaggtttc ctgtttagtt
tctgaggtgt gctctaaatt gttgggtttg ccttgaaact aacttttgtt attggcatat cagtaactat gcatcaatct gtaactattc tgaagcacca
tagagcccat agaacagtgg gaactttgaa aaggaaacta gagttagccg tgcttctcaa gaaaataata gtccgcaaaa ttcacatagg ccaactgtga 500
aaaataggat atttttgtga ccatatccat gccaaagata ttggagcgat ttaatgacag atcttttaat ccggaaaggg aaatgtgctg gtatgttctg
gaggatagat gggatttgaa taagtgtatt ccaacaccac atctcctcaa ggtaagcaga caatcaggaa gagtgatact gcaaagcaat tgaacaagca
ggcagggatt acagaagttc agtagggctc tggaaaggct gagctcagtg tgaagttgga agagagtatg ggcttatctt gaagccaagc ttactgtctt
cacttgtatg gttgtttaga ccgaatttga taggttaatc gggactatgg agagatgctg tttccgtccc cctgcagcaa taatagtaac aacaacaata
acaatttcat atattttcta cgatggaatg tctaaaatca gaagccaga gcagggacaa ctgcagataa cgcacaaagg cagtttatac tttttacagc 1000
attgggagcc actgccaaac gcagaaagaa aaccggaaca cagcaactta agacaaccaa caatttaaag agcatctgtc acactctatc acatttgtct
gacacagcgt caaagagaat gacgctacct ctgaatggca gtacagaaag tgggaggagg gggcacaatg ggactgagga gacagacggc caggtcgata
gggatatgaa ctaagaagct gttcacgtat ccacggaatg cggaaatgag gacccagacc gaggccagtg gccaaactat ggactagata acgaccatcg
agagacggtt tcaacggaca cggaccactt agccttgttt atgattggtt aaaggaaaaa aaacctcgat aatcgcaaga tgtatttata tttttttctt
gcttgtttgt tctgctgctg ctgttgctgc tgctgctcaa ctcaggctgg tcttgaactc ttgatctcct cctgagcttt aactctgagg tgtgagcccc 1500
atgcagattt actttgtata gccagaaaca accccccccc acacacacac acaataatta gtaaagccac cgagaacaag gaaccccaga gagatcaaga
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gaataggttt atcttcagat aagattaagg aaagccagtt caggaacaga gattaggacc agtacagacc agaggaggtg gtggctattg tcacctttaa
ctctgggttg gcactttcaa cacaaccccc ccccccccaa aaaatagacc atttagtggc agctttttaa aggtgaaaga agaaacctct ggatctacag
tagtgtatgc ctgtaatctc agcatgtggg cctgtgaagc agaaacatca gttcaaagcc agactgggtt cttacattct gggatcctgt tctttaaaaa
gagagagaat gaacaaggga tagagaaata gaaaggggaa ggaagaagag agaaagaaag gtaagggggc aggaaaaagg ggagtggagg agaattgagg 2000
gaaagaaagg aaagggaaag gaagatattg cttttattaa aacaaaaaca gggccggaaa atggttcaga ggttaagagc actgactgct cttcctgggg
tcctaagttc aattcctaac tatttgtaac gagatctggc gccctcttct gacatgcagg catatatgca gacagaacag tatacataat aaataaacgc
atctttaaca acaacaacaa caacaacaac aacaacaagg gactggagag ggtagctcga cgtttaagag cattggctgc tcttccgagg acccggttca
tttccgacac ccacatgcgc tcacgctgtc tacactcagt tcaggggatc taactctcac acgatgaaca ccatgacaca aatagataat aatcttttta
aaaaatgaac aacaacaaca acaaaaaccc ataaaccaaa acaaaaaatc tctgtgttcc tgcatcctcc tgatctgtcc cttccttgtg tcccttagGG 2500
AACGGCCACA GTCTACTACT TAGCTTTAGA TGTGATAGAG TCTGACTGTT GGGTCCTTTC CACAAAAGCC CAGGATGACT GTCTTCCATC GAGGTGGCAA
TCTGAAATAg taagtaactg ggaccactgg gctcctctca ccattcttcc ttctagtccg ctcactcacg ggagccaccg ccacatgctg ggctaccaca
atgggaaaag atgctgggtg atttaagatt cacacagatg atattaactt tcaattgtac tcttgtggcc gcctgagata acatcaccag cttcaagtct
taggcaaatc agcaaacatc tttagacttc agtatatgga ctccagtgtt gtttccagac cacacagcct atgcatttat gaactgggat tgtgtgctgc
gaagactgcc ggtagcagtg atggccaccg ttgcagtgag gaactaggtc tcatcttgtg tatactggat actgaggcca gtctccctgt cgtaagtgag 3000
agtgcaaagg aatgagcaga cacaggagtc caagtcctga agtgagaggt ttacacactg aggggctcta tctagtccgt ccttctttga aaacatttgg
ggtattgtca cagtccactt aaacaggtgt tctcatgagg gtttggggtg ccagtggtgt gcagctcaca gtctgagaga agactgatgg agaaaccccc
aaacacacgt tatgagagat ggtggctgtg tttcctcaaa gtcaaactgg ggttccataa gggcttaaaa tcctcttctt ttacagGTGA TTGGACAATG
TAAGGTAATA GCCACAAGAT ACTCAAATGA GTCTCAAGAT CTTAGCGTGA ATGGCTATAA CTGCACCACA AGTTCTGgta aggtcatctg ctgaattgca
tagaactcag ccataccgtg gtatccattc tgtaacagcg ttatggaata ggagagggtg cctgtccttg tgttgtccat taattagtac gagtctcctg 3500
acattagaca gagcacagct ccttgcctct ggcatacctc acttaaagag aattactgta tagatgtgga aattaattgc agagacttag ttctgaggtt
aggccggctt gagcttgaag ccgaacctca ttatttaccc gttctttctg agtcaacact ttctgagatg gaatcatgtc gtcattgtgt ctactttatc
tccagagtaa ttgtgacttg gggagcaggt tacttaatcg atttaggctt tcctcgttta gaattcttgt tggaattaaa tagaatgagg atgctttgca
gaattcttag tccttgataa gaattggctt caacaagttg aaagttctat attccagtat ataaagtatg ttatatactg tgttatctag tgccaatcat
tccatttaat ctcacacaag gctatgaagt aaatgttgtc gaacttttta ttgcagagat aaaaataatt ggggccggca aagattccaa ggtgtgttct 4000
cagaagcaca ctgaggcaaa gaatgctata tctacatctc tacagtgttg actctagagt ccagactctt aagtatttta gtatttcttc aaaaagaatt
aattaggttt gttttgtttt attgtttgtt tgttctttca tgagacaggg tttctctgtt tagccctggt tgtcctggaa ctcactttgt agaataggcc
ggccttgaac tcgcagagtt ctccctgcct ctgcctgctg aatgttggga ctaaaggcat ggtaccgctg cccagctaag aattaatttt aaaggggcat
atttcagctt gaacagctga gcagttcaga ctgaacagca ttaacaacac agcagcttct acaggaaatt gcttttaaaa aaccgagaga agcaaggcgt
ggtgttatag gcctatattc ccagcactcg ccttggtgtg ggtctgaggg tagctacagg gtgattccct gtggatgatt ccctgtgggg agagagagag 4500
aggggagaag ggagagggga gggggagggg cagggggagg gggagggaga ttgtgtgcaa ccattttctg tagccttaac ttaaagcttc cattctctcc
ttgacaaaga aaggaagcac agaagcatag ctctttcagc actttgtgaa ggccggaatg ggcgtggcgt cgtggatgga ggtcatacag agcggcaggg
aagaacagct gctgcctcgc tgattggatc ttgacaagtt attttaacct tcagttagtc catctgtaat aacagcgtcc ctctccgggc tgtgcttaca
tgtgctgtat tctgatctag tgttgatgtt gccactgcca actctgaccc tgtgacatgg ctgtctttct ctttcctcta gTCTCTTCAG CACTTCGCAA
TACCAAGGAC AGTCCTGTAC TCTTGGACTT CTTTGAGGAT TCCGAGCTCT ACAGAAAGCA AGCCCGTAAA GCCCTGGACA AGTACAAAAC GGATAATGGT 5000
GACTTTGCCT CTTTCAGAGT GGAACGGGCA GAACGGGTTA TAAGAGCGgt gagttcccac taccgcagcc tggcgggggt gagctgagcg cctagccctg
tacactgtac acctgtctca cttgggcagc tgccttttaa atcgttgcag cctttgatgc ttagtgaagc gcaatcccat aaacttctct tactgaagag
acaatgggat gaggatggaa ttattatctg acagaaaaaa gaagccaaag gaaaggcaag agcattactg gattacttga gcactaaaaa acatccagtg
ttagcgtcct tatggtagaa tactgaggct tgtggatcta gaattctagt gcgtcctacc cagagctgtt atgtggaaca gacagttaat gttttggctt
tttttttaag tatgtatttt taagatttat ttgtttattt gtgtgtgtgt gtatgtgtga gtatgtgttg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 5500
ctgagccccc agaggtcata agagggcatt ggatctcctg attgggaatt gaactggtcc tttgaaaagg cagtgagtac tcttaaacac tgaaatatct
ccccagccct gccaagtatt ttgaaaaggg aaaatcaaat agatcatggt gtttcaagca atgggacgcg tataacgtgg catcctatga agaatgtgct
gaaccaatag gcactggcag gagagaagaa ggcttcacac aatattctag cattatttaa acacctgcat gcttctacat gcaggcaaag actgtataag
gagaagcact tcaaaccagt gggaacagag ctgaggagat ggcccacagg ttaagagcac cgactgctct tccagaggac ctgggttgga ttctaagaac
ctatgtaatg gctcacaatc atctgtaact cttgatccgg atcatctgac accatcttct gacctcctta aacagaagca tatacaagaa aaacacctca 6000
tgcataaaaa cataaaacaa acaaacaaac aaaaaagtaa cagtgactcc ccccaagaat gtggatctgg ggctcagggc gactgttttt ccctgctatg
cttctgcctg tatactacag aatttctgga aaatggtgat ctcttatcac tgatgtaata tatttttatt tggcagcaac caaaggaaaa tagcatgtat
tcatcatttt aattcccata gtgctttaca agatgttgtt taatggctat ctgttacttt tcctcttagc ttttatgctc atgagaccat gttgattcct
ctgttctagA GAGGAGGGGA AAGAACCAAT TACTATGTGG AATTCTCCAT GAGGAACTGT TCCACACAGC ATTTCCCCAG GTCCCCTCTG gtaagtatgg
tgcgctgtca ttgagagagt gcctaaggga ctcctcatac acatgttcac tgactaacac tctagtgtca caccacccta gaagacaagc acacatattc 6500
cttctgattt aaagatggag agatggtttt agaatataca ttgcattata tacatatgcc tagaattgaa ttttcaattc tttaagacta aaggcttagt
gagctaataa ccagcctgca ctaaggccat ctacaccaag aattgatgct tgcaggtatc ccagatgaca agtgaggaca ttactgtggc cctgccaagc
ttggttagaa tccagcactt cttccttaat cagattgacg cattatttgc tggaaggtct tactgacgat acccaatatt tcctcccttt agtccttgat
tagtagggtt tttttggtca tcatgatgag aaaatgacta aagcacttcg tatcttggtg tttacaaagc atctccacat acattattgt ctgctgagct
tcctgacagt cccaatgtgg agattcaagt gtctggctca cttacctgtg cactgttagt tagttaattc tcaattcgag ggcttttctg gggtttaatg 7000
gcacctccac tttccccagc cagaagggga gaggcatgtg ctgggtcatc aatttcacaa atgcaaatgc atgcttatat atatacacat tccagctgct
caaagttccc acttgagcca gttctagatt cctccttaga agccccaaaa gacaaacact tcgctgtgtt tgtgtggtgc taaaaaccca ctgcagagtc
atgaaggttg gagaaggaga agctagcagc ctcccctcat gtaatcaaag ctgcttgtac ctgtgggtat cccactcatt tgcaaacact gaatttcaga
atctttgtcc aattcatttc ccactgctgc taactggcaa gtccacattc atataggtct ccttgacttc caaactctac agacagcctc aacacctagc
tttctttaga aatgaattgt cttcttgtcc tttgacaaat gggtttaggg gcttccggaa cacagaatgc cagccagtta gagccatcag acactcacat 7500
taacagggct caagcaaacc catctttgta gtggctctgc ccttcccagc atttgcaagt tacacaaatc tgtcttcaac agcatttccc attctcccag
gcacaagcca cccaggtctt tattgcagaa acactaacct aagggcagca gggacatgtg ttcctagtac tatatacaag tgtgcagtgt gtctgttcat
ggaagaaacc cacagaagcc tgataaaaac ctgtggaacc ggtacttctt ccaagtgttg actatgtgac aataataaat aacagatgtg gtgtgtgata
tagtattgtc tttcattttc cttctttgtt tgggtgtggt gcatgtatgt caaagattcc ccaaggaaga tacaaaccct ttcctctagt tcatgtaaag
cttttcttgg ctaaaaacat cacacccctg tggacacaca catgtatgga cacattcact gtatacccct cttgcacatg ctaacaggca tttccctttg 8000
aagGTCTTTG GATTCTGCAG AGCACTTTTG TCCTACAGTA TAGAAACCTC TGACTTGGAA ACCCCAGATT CCATTGATAT AAACTGCGAA GTCTTCAACA
TTGAGgtggg ttgactgagc atccttcatc gtgagcagaa ccagaccaag tgacaatttc tcttgcatag tacatttggt tcatttgagt cttatgatgt
gtgtgtgtgt gtgtgtgtgt gtgtgtatac atgtgtatga gcatatgtgt gtacatatgt gtgtacatgt atatgtgtgt gtgtgtgtgt gtgtgtgtgt
gtgtgtgtat aagagacaga aagatagaca cagaatcaca gagtaggttt gttgtcacca aaaacatgac tccatagatt ttgtttgctc ctttgttgtt
ttgttttgtt ttgttttttt gagacaaggc ctcactaagt agcattggct aatctggaac tcactgtata aattaaactg gcctcaaact catagagatc 8500
tgtccacctc tggcttctta gtgctgagat taaagttgta cactgcgaca catagccaga tgtatagcac catgcctaac catagttttt tttttaatta
aagtgtgttt tggtatacaa ctgtaattct aatatgtggg aaactgaaaa agaaaaatag tcaagttcca ggccaggctg agctacagag aaaaactctg
ggtttttttt atttgtttgt ttttaaaagc taaagctgag gttgagaagt tcaggtgtct atcttctgga gagtgttctt gggactgtgt tgagaatgtc
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agatccatca aaaattctac tttaataggc agttccttga tagagtttca tcacttttca ttgacacgag aaaaaataag tttaatacaa tttttcataa
aacagcatgt gccggcacac acctttaatc ccagcacttg ggaggcagag gcaggtggat ttctgagttc gaggctggcc tggtctacag agtgagttcc 9000
aggacagcca gggctacaca gagaaaccct gtcttgaaaa accgaaaaac aaaacaaaac aaaacaaaaa caaaaaacaa aaaataaaac agcgtgtagt
ccagccaaag gatcactctt acacattagc tttctaattt gtcatattcc tcttgggaaa taatcgtgct attcaacgac acattttttt tttttaattt
taaatgtaat ttggctagaa aaaaaaatgt aagaaccaga gctggagaga tgactcagca gttaagagta tttattgctc ttccagagga ccagggttca
attcccagcc ccatatggca gctcatggct gcctgtagct ccagttctag gggatctgct accttctctg gcctccacac cccccccccc cacacacaca
gtgcatagac atacatgcag gcaaacccct acatatagta attttaaaaa aaaatcaatg ttttttgggg ggtatcctac ttcttaaatc aatttgtgaa 9500
atctttgagc gcctccagtc tgaatcaagc ctaacatcta acttcttaca taattgtatt tatgtctctg tgtcctttac cagGATCATA AAGACACAAG
TGACATGAAA CCCCATTGGG GCCATGAGCG TCCTCTTTGT GACAAACATC TGTGTAAGCT CAGTGGATCC AGGGATCATC ATCATACCCA TAAGACAGAT
AAACTTGGAT GCCCACCTCC ACCAGAAGGA AAAGATAACT CAGACAGACC ACGCCTTCAA GAAGGAGCCC TTCCACAACT GCCCCCTGGC TATCCCCCTC
ATTCTGGTGC CAACAGAACC CATAGACCCT CTTATAATCA CAGTTGTAAT GAGCATCCTT GTCATGGACA TCGTCCCCAT GGACACCACC CCCACAGTCA
CCATCCCCCC GGTCACCATT CCCATGGTCA CCATCCCCAC GGTCACCATC CCCACAGTCA CCATTCCCAC GGTCACCATC CCCCCGGTCA CCATCCCCAT 10000
GGTCACCACC CCCACGGTCA CCATCCCCAT GGTCACCATC CCCACGGTCA CCATCCTCAT GGACATGACT TCCTTGACTA TGGACCTTGT GACCCGCCCT
CCAATAGTCA AGAACTCAAA GGTCAGTATC ATCGGGGCTA TGGTCCACCA CATGGACACT CAAGAAAAAG AGGTCCAGGC AAAGGACTCT TTCCTTTCCA
CCACCAACAA ATTGGATATG TCTACCGACT CCCTCCACTG AATATAGGTG AAGTTCTCAC TCTTCCTGAA GCCAATTTCC CCAGCTTCTC TTTGCCAAAT
TGCAACAGAT CCCTACAACC AGAGATTCAG CCCTTCCCTC AGACAGCCTC CAGGTCATGT CCAGGGAAAT TTGAGAGTGA ATTTCCACAA ATTTCCAAGT
TTTTTGGATA TACACCTCCA AAATAAAACC TGATTCCTTG GTAGGGGGAA GAGGACAATA TTCTGAATAA ATAAAATATG ATGAGTtaga aatgaaaagt 10500
gtaactactt taactttggt ttcatacata gggaagtatg ggaaagaagc cagaatgaga cagatgggca aatggagatg agaggaaaga tgttgtcttg
gtcagggttt ctattcttgc acaaaacatc atgaccaaga agcaagttgg ggaggaaaag gtttattcag cttacacttc cacattactg ttcatcacca
aaggaagtca ggacaggaac tcacacaggc caggaacttg gaggcaggag ctgttgcaga ggccatggag gaatgctgct tactggcttg cttctttctc
gggttgcttt cttatagaac ccaggaccac cagcccaggg atggcaccac ctgaaatgag ttctctcacc cttgatcact gattgagaaa atgccttaca
gctggatctc atggaggcat ttcctcaagg gaggctcatt tctctgtgat tactccaact tgtatcaagt tgacacacaa aaccagccag tacagatgtc 11000
aatgctagga accagaggtg aagtctgtct cttggtattg agtcagttga ggcaaatatg acacccagaa tttctctctg ccttgagtta actccctaat
tcttgagtct ctgttctagt cgtgctatag ctgggtgtat taccttcttc tctgctatga tgataaaata ctgggaccaa ggcaatttaa ggaagagaga
gtttattttg gctatggtac cagagagatg agagtgcatc atggtgggga gtcgtgggag caagtggcag gcgtgtgaag aggagcagga agctgagaac
tcacaagtca agcataaagc agaaaacact aactagaagt gacaggaggc ttttcatttc aaaggctgaa tccaatgaca tattccccca gcaaagccat
accgcctaca catccccaga caacaccaca aactggggac acaatgttca catatctggg cctatgggac cattctcatt caaacggata aagtgggcat 11500
accaagaaag tacatattgt tttaatatat tattataaga gtcacattgt ctcctaatga tttctagtct aaattcaatt ctgaaatgct tagtagccgg
gtggtggtgg cgcatgcctt taatcccagc acttgggagg cagaggcagg cgaatttctg aatttgaggc cagcctggtc cacaaagtga gttccaggac
agccagagag ccagggctac tcagagaaac cctgtctcga aaaaccaaaa aataaaatgc ttagtaaaac tggctagtca agcagtggtg gtgcatgctt 11800
tt gtgcatgctt 11802
Figure 3.5: Structure of themouse Hrg gene.
A Restrictionmap of theHrg locus. Exons are indicated by black boxes and Hrg clones isolated from the
129 SvJ and RPCI21 libraries are aligned below. Solid bars depict areas sequenced and deposited in the
GenBank nucleotide sequence databases under accession numbers indicated. Restriction enzymes in
this map are BamHI (B), EcoRI (E), HindIII (H), and ScaI (S).
BNucleotide sequence of themouseHrg gene. The genomic fragments sequenced cover a total of 15480
bases including 3678 bases upstream from the translation start codon ATG. The nucleotide sequence
from -1789 to 11802, first 10 bp of which are underlined, was determined on the clone isolated from
mouse genomic 129 SvJ library and deposited to the database (GenBank Accession No. AB055898,
Tsuchida et al., 2001). The nucleotide sequence between -3679 and -1187 was subsequently determined
on the clone isolated from the mouse RPCI21 genomic library. The base numbering is based on the
codon for the initiationmethionine as number 1. Exon sequences are presented by red capital letters.
3.1.4 Repeat sequences of mouse Hrg gene
Sequence analysis of the mouseHrg gene using the RepeatMasker WebServer (http://p.genome.
Washington.edu/cgi-bin/RepeatMasker) revealed thepresenceof short repeat sequences, (CCAA)n,
(CAAAA)n and (TTTA)n at positions from -3026 to -2996. Additional short repeats, (CTG)n,
(CAA)n, (CAAAAA)n, (TG)n , (TG)n, (TTTTG)n and (CAAAA)n occurred dispersed through-
out the introns at positions 1413-1438, 2208-2238, 2401-2448, 5441-5501, 8199-8309, 8397-8418,
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and 9041-9092, respectively. Exon VII includes 14 tandem 15 nucleotide-repeats at a position
11640-11849 corresponding to Gly-His-His-Pro-His repeats in HRG.
3.1.5 HarrPlot analysis of human andmouse Hrg genes
Next, a Harrplot analysis (Harr et al., 1982) was performed to survey the homology of the human
and mouseHrg gene (figure 3.6). ´is Harr-plot analysis indicated that the exons of mouseHrg
gene have high sequence similarities with that of the humanHRG gene, but the introns showed a
low similarity. Interestingly, the second introns of each cystatin domain, intron B and intron E,
have a higher degree of sequence similarity than the other introns of the human and mouseHrg
gene.
Human HRG Gene (13222bp)
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Figure 3.6:Harr-plot analysis of the humanHRG gene andmouse Hrg gene.
Exons of human HRG andmouse Hrg gene are shown by red and blue lines, respectively and the introns
are indicatedas letters (A-F). Diagonal stretches of dots indicate highhomology regions betweenhuman
HRG gene andmouse Hrg gene sequence as seen in the exon regions as well as in intron B and E. The
base numbering is based on the codon for the initiationmethionine as number 1 (see figure 3.5 on the
facing page).
´eHarr-plot analysis of the 5’-noncoding regions of mouse and human is shown in figure 3.7
on the next page. ´e sequence at the positions -5 to-377 and -1417 to -2067 upstream of the
transcription start point in the mouseHrg gene are well conserved between the mouse and the
human sequence.
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human HRG gene
-5
-377
-1417
-2067
-1-419-969-1584
Figure 3.7:Harr-plot analysis of the upstream region of humanHRG gene andmouse Hrg gene.
The base numbering is based on the codon for the initiationmethionine as number 1 (see figure 3.5 on
page 36). Diagonal stretches of dots indicate high homology regions between the humanHRG gene
and themouse Hrg gene sequence.
3.1.6 Predicted transcription factor binding sequences and comparison of human
HRG gene andmouse Hrg gene in the promoter region
´e 5’-noncoding regions of mouse and human HRG genes are aligned in figure 3.8 on the
facing page. Computer-aided sequence analysis using the TRANSFAC database predicted the
transcription factor-binding sequences in mouseHrg gene (http://transfac.gbf.de/TRANSFAC/).
A classical TATA box-like sequence was found to be missing, but several candidate sequences
for transcription factor binding motifs were detected; three sites for C/EBP beta like enhancer-
binding proteins (C/EBPbeta), which participate in the cAMP induction of the PEPCK gene
(Croniger et al., 1997), two sites for Oct-1-like octamer binding protein (Oct-1) known as a
ubiquitously expressed protein (Petryniak et al., 1990) one each for Id3-like inhibitor of differenti-
ation (Id3)/DNA binding protein (Chaudhary et al., 2001), hepatic nuclear factor-1C (HNF-1C)
like hepatocyte-specific transcriptional activators (Bach and Yaniv, 1993), nuclear factor of ac-
tivated T-cells (NF-Atc3) (Rao et al., 1997), PR like progesterone receptor (Shemshedini et al.,
1992), AP-1-like transcriptional enhancers (Campbell et al., 1991), GATA-1-like tissue-specific
DNA-binding proteins (Tsai et al., 1991), T3R-like thyroid hormone –3 receptors (Samuels et al.,
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1988) and COUP-like chicken ovalbumin upstream promoter (Pastorcic et al., 1986).
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Figure 3.8:Comparison of the humanHRG gene andmouseHrg gene sequence in the promoter region.
The nucleotide sequence between positions -457 and -1 of themouse Hrg gene in figure 3.5 on page 36
and that of the corresponding region of the humanHRG gene (Wakabayashi et al., 1999) are aligned.
Identical bases are shown in red. Putative transcription factor-binding sites are overlined and abbrevi-
ated, according to the TRANSFAC database transcription factor nomenclature.
3.2 Generation of HRG null mutant mice (Hrg“j“)
3.2.1 Construction of the gene targeting vector
A targeting vector for homologous recombination including the possibility of a positive-negative
selection of recombinant cell clones was constructed as shown in figure 3.9 on the next page. A
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1.9-kb SalI-XbaI fragment of mouseHrg gene including a part of the 5’ region and a part of exon
I was inserted as 5’ homology region into the polylinker site 1 of pGKNEO vector, which was
opened by XhoI and AvrII digestion. A 7.8-kb BamHI genomic fragment of mouse Hrg gene,
which contains exons II to VII, was inserted as 3’ homology region into the polylinker site 2 of
pGKNEO vector, which was predigested with SalI and filled with dGTP and dATP in the BamHI
site. ´us, the targeting vector was constructed by replacing a 1.8-kb XbaI-BamHI fragment
containing exon I with a 1.8-kb neomycin cassette for positive selection of resistant clones.
NEO Replacement
    vector
 H
Wild-type
    allele
 10.4kb
 4.6kb
Targeted 
    allele
1kb
 probe 
 8.4kb
 6.5kb
 B
 S H  H  H
P1 P23091bp
 S
 S S
NEO
 H  H
P1 P32077bp
 S  S S
 probe 
Figure 3.9: Strategy for the targeted deletion of the Hrg gene.
Themouse Hrg wild-type allele and its partial restrictionmap are schematically drawn on the top. The
replacement vector is shown in the middle. The 3’-portion of exon I and the 5’- half of intron A were
replaced by the neomycin cassette in the targeted Hrg gene (bottom). Restriction enzymes in this map
are BamHI (B), HindIII (H) and ScaI (S). Exons are represented by black boxes. The position of PCR primers
(P1, P2, and P3) and the sizes of the expected PCR products are shown beneath the alleles. Restriction
fragments digested by ScaI (blue line) or HindIII (red line) are indicated with their sizes (10.4-kb and
6.5-kb or 4.6-kb and 8.4-kb, respectively), above the wild-type or the targeted allele. The fragments can
be detected by the indicated probe (black bar) by southern blotting analysis. Note that the probe as well
as the primer P1 are located in a 5’-position to the 5’-homology inserted in the targeting vector to make
sure of the correct homologous recombination.
3.2.2 Establishment of a southern strategy for the screening of the Hrg alleles
To establish a southern strategy for mouseHrg gene targeting, some putative southern-probes
were isolated from the pPAC4 cloneDNAwhich are located upstream of the 5’-homology inserted
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in the targeting vector. Possible candidates were SmaI 0.6-kb, PstI 0.6-kb,HindIII/BglII 1.9-kb and
PstI 1.2-kb fragments (see figure 3.10). To test if the putative southern probes contain repetitive
sequences which are oen distributed over the genome, the restriction fragments were blotted
and hybridized with mouse genomic DNA as probe as shown in figure 3.11 A on the next page.
´e SmaI 0.6-kb and PstI 0.6-kb DNA fragments (figure 3.11 A, lane 1,4) were not hybridized
with mouse genomic DNA probe. ´is result suggests that these probes are good candidates for
southern-probes.
In the next step southern blot analysis with genomic tail DNA digested withHindIII or ScaI
was performed. Genomic DNA transferred on a positive charged membrane was hybridized
with SmaI 0.6-kb and PstI 1.2-kb DNA fragments, respectively (figure 3.11 B, C on the following
page). Interestingly, although smear bands were detected with PstI 1.2-kb DNA fragment, clear
and predicted bands were detected with SmaI 0.6-kb. ´ese results demonstrated that the SmaI
0.6-kb fragment is a suitable probe for genomic southern blot analysis. ´e two larger fragments
HindIII/BglII 1.9-kb and PstI 1.2-kb were not suitable as probes because they contained repetitive
sequences (figure 3.10, blue bars).
SmaI 0.6-kb 
PstI 0.6-kb 
Sequence of 129SVJ library
5' 3'0
HindIII StuI
0.6 1.1 1.8
KpnI
-0.1
BglIISacI
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EcoRI
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StuI
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-2.0 2.6-1.0
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-0.16
-0.7
-0.8 0.35
BamHI EcoRI HindIII
0.1
AvrII
SpeI
-0.3
HindIII/BglII 1.9-kb
PstI 1.2-kb
Sequence of RPCI21 library  
(kb)
Figure 3.10: Isolation of southern-probes from RPCI21 genomic library and restriction enzymemap of
PAC clone includingmouse Hrg gene.
Isolated DNA fragments for southern probe, are shown by green bar. Repetitive sequences are shown by
blue bar.
3.2.3 Gene targeting in ES cell
Embryonic stem cells (passage 10) were electroporated with linearized Hrg-neo replacement
vector DNA. Positive-negative selection was done using G418 and ganciclovir, respectively. ´e
afore mentioned steps were performed by Dr. Silke Ensslen and Dr. Markus Moser. ´e genomic
DNA from 144 neomycin resistant cell clones was isolated and analyzed by southern hybridiz-
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Figure 3.11: Test blotting of southern probes.
A, Isolated probe candidates were blotted and hybridized with mouse genomic DNA probe. Lane 1,
SmaI 0.6-kb; Lane 2, PstI 1.2-kb; Lane 3, HindIII/BglII 1.9-kb; Lane 4, PstI 0.6-kb; Lane 5, mouse genomic
DNA as positive control.
B, Mouse genomic DNA and PAC DNAwere blotted and hybridized with the SmaI 0.6-kb fragment. Lane
1, genomic DNA ofmouse kidney digested with ScaI; Lane 2, genomic DNA ofmouse kidney digested
with HindIII, Lane 3, undigested genomic kidney DNA; Lane 4, 21pg of pBluescript vector digested with
EcoRV as negative control, Lane 5-7, 7ng, 3.5ng and 0.7ng of PAC DNA; Lane 8, marker 1kb DNA ladder.
Expected bands are depicted with arrows.
C, Mouse genomic DNA and PAC DNA are blotted and hybridized with PstI 1.2-kb fragment. Lane 1,
genomic DNA ofmouse tail digested with ScaI; Lane 2, genomic DNA ofmouse kidney digested with
ScaI; Lane 3, genomic DNA ofmouse kidney digested with HindIII, Lane 4, undigested genomic kidney
DNA; Lane 5, 21pg of pBluescript vector digested with EcoRV; Lane 6-8, 7ng, 3.5ng and 0.7ng of PAC
DNA digested with HindIII; Lane 9, marker 1kb DNA ladder.
ation analysis aerHindIII-digestion (figure 3.12 on the facing page) and additionally by PCR
(figure 3.13 on the next page). PCR analysis verified the presence of a neomycin resistance cassette
in all clones (not shown). ´e southern blot analysis revealed a 8.4-kb fragment corresponing to
the correctly targeted allele clearly distinguishable from the 4.6-kb DNA fragment characteristic
for the wild-type allele. ´ree correctly targeted embryonic stem cell clones (clone Nr. 24, Nr. 33
and Nr. 130) were identified among a total of 144 neomycin resistant clones corresponding to a
targeting frequency of 1 in 48.
3.2.4 Generation of HRG null mutant mice (Hrg“j“)
Two independent ES cell clones (No. 24 and 33) were successfully used to derive chimeric mice
aer blastocyst injection and embryo transfer. Two male chimera derived from ES cell clone 24
and one female chimera derived from ES cell clone 33 sired progeny with C57BL/6 wild-type
mice. ´e generation of the HRG-deficient mice was performed by Dr. Silke Ensslen. Genomic
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Figure 3.12: Southern blot analysis of the genomic DNA isolated from ES cells after homologous
recombination.
The DNA probe as indicated in figure 3.9 on page 40 detected a 4.6-kb HindIII fragment in the wild-type
allele and a 8.4-kb HindIII fragment in the mutant allele, respectively. Correctly targeted embryonic
stem cell clones are shown by red arrows.
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Figure 3.13: Confirmation of homologous recombination at level of ES cells.
PCR detection of the disrupted allele was accomplished with forward primer 1 (P1, see figure 3.9 on
page 40) derived from the 5’ non-coding flanking region of the Hrg gene and with reverse primer 3 (P3),
located in the neomycin cassette. Thus the PCR generates an amplicon size of 2077 bp for themutated
allele. DNAmarker size in kb is indicated on both sides.
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DNA analysis by Southern blot or PCR analysis of the F1-progeny with brown fur color indicated
the presence of one wild-type allele and one null allele derived by homologous recombination
at theHrg locus. One clone 33 chimeric female and one clone 24 chimeric male transmitted the
targetedHrg locus through the germline.
Mice of all threeHrg genotypes were born from crosses of heterozygous F1 offspring. Typical
results of genotyping by southern blot and PCR are shown in figure 3.14 A and B on the facing
page, respectively. Ten matings yielded a combined progeny of 98 mice comprising 30Hrg+/+, 34
Hrg+/-, and 34Hrg-/- mice illustrating that HRG-deficient mice are viable. Progeny derived from
different injection experiments were phenotypically indistinguishable. ´erefore we expanded
and maintained only one line derived from clone 33. ´e HRG null mutation in its homozygous
state wasmaintained on amixed 129/Ola×C57BL/6 background. For further reference themutant
strain is named 129/B6-Hrgtm1Wja according to ILAR (Institute of Laboratory Animal Resources)
rules.
3.3 Analysis of HRG-deficient mice
HomozygousHRG-deficientmice were viable and fertile. Spontaneousmortality during the first 3
months was normal at 2.6 % (seven out of a total of 268 animals). To verify if the targeted deletion
resulted in HRG-deficiency also on the protein level, immunoblot analysis were performed. ´e
first screening of animals of all three genotypes included a standard hematological analysis of
mouse plasma as well as routine serum chemistry. ´e results of the examined blood parameters
are shown in the following.
3.3.1 Immunoblot analysis of serumHRG expression
To confirm theHRGdeficiency in serum, immunoblot analysiswas performedbyDr. Cora Schäfer.
Figure 3.15 on page 46 shows that two protein bands characteristic of HRG (80 kDa) and its major
proteolytic degradation product were detected in the serum of wild-type and heterozygousHrg+/-
mice, but no protein band was detected in serum from Hrg-/- mice. Roughly half the amount
of HRG protein could be detected in serum from Hrg+/- mice compared to Hrg+/+ mice. ´is
finding indicates that both copies of the Hrg gene are expressed independently. We obtained
identical results when we analyzed HRG levels in serum from the offspring of ES cell clones 24
or 33 (figure 3.15 A and B on page 46, respectively), indicating that both strains represented
a true HRG null mutation at the serum protein level. For further analysis the progeny of the
HRG-deficient strain 33 was used.
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min human 125I-labeled fibrinogen (Amersham, Buckingham-
shire, UK) and was coagulated at 37 !C with 8 lL of bovine
thrombin (75 U mL)1) (Sigma), and 10 lL of 0.75 mol L)1
CaCl2 solution [27]. At the times indicated the
125I content of
50-lL aliquots of supernatant was measured using a gamma-
counter (model LB 951 G; Berthold, BadWildbad, Germany).
The release of 125I-labeled fibrin degradation peptides was
analyzed by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and autoradiography using 10 lL of
lyzed clot supernatant and NuPAGETM acrylamide gels
(Novex, Frankfurt, Germany).
Induction of skin wounds
Mice were anesthetized, shaved dorsolaterally and swabbed
with 70% ethanol. A full thickness wound was inflicted using
an 8-mm dermal biopsy punch. Wound areas were photo-
graphed daily and the wound area was measured histomor-
phometrically using National Institutes of Health IMAGE
software.
Results
Structure of the Hrg gene locus
Figure 1 shows the structure of the mouseHrg gene locus. The
complete nucleotide sequence of 13 591 bases (AB055898) was
determined by sequencing. The alignment with the cDNA
sequence demonstrated that the gene for mouse Hrg was
composed of six small exons I throughVI (81–225 bp), and one
large exon VII (905 bp). The size of introns varied from 677 bp
to 2315 bp. This exon–intron structure was very similar to that
of the human gene [28] where seven exons were likewise
identified. The structural organization into two groups of three
exons coding for a cystatin-like protein domain each, and one
additional larger exon coding for a third protein domain
specific for the respective protein is also present in the related
fetuin family proteins, Fetuin-A/Ahsg and Fetuin-B/Fetub
[24,29]. The genes encoding these proteins are neighbors on
chromosome 16 in the mouse genome and therefore originated
by gene duplication. A similar arrangement is conserved in the
human genome.
Generation of HRG null mutant mice (Hrg–/–)
A targeting vector for homologous recombination was con-
structed as shown in Fig. 1. Upon genomic Southern hybrid-
ization of DNA isolated from 144 neomycin-resistant cell
clones three correctly targeted embryonic stem cell clones with
the predicted restriction patterns (Fig. 1) were identified. Two
independent ES cell clones were successfully used to derive
chimeric mice after blastocyst injection and embryo transfer.
Genomic DNA analysis of F1-progeny of these mice indicated
the presence of one wild-type allele and one null allele derived
by homologous recombination at the Hrg locus. Mice of all
three Hrg genotypes were born from crosses of heterozygous
F1 offspring (Figs 2A,B). Ten matings yielded a combined
progeny of 98 mice comprising 30Hrg+/+, 34Hrg+/–, and 34
Hrg–/– mice illustrating that HRG-deficient mice are viable.
Progeny derived from different injection experiments were
phenotypically indistinguishable. The Hrg null mutation in its
homozygous state was maintained on a mixed 129/Ola,
C57BL/6 background. For further reference the mutant strain
is named 129/B6-Hrgtm1Wja according to ILAR (Institute of
Laboratory Animal Resources) rules.
Analysis of HRG-deficient mice (129/B6-Hrgtm1Wja)
Homozygous HRG-deficient mice were viable and fertile.
Spontaneousmortality during the first 3 months was normal at
2.6% (seven out of a total of 268 animals). We performed
immunoblot analysis to confirm the HRG deficiency in serum.
Figure 3 shows that two protein bands characteristic of HRG
(80 kDa) and its major proteolytic degradation product were
detected in the serum of wild-type and heterozygous Hrg+/–
mice, but no protein band was detected in serum from Hrg–/–
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Fig. 2. Confirmation ofHrg gene knockout at the level of genomic DNA.
(A) Southern blot analysis of genomic DNA isolated from tail biopsies
of Hrg+/+, Hrg+/– and Hrg–/– mice. The genomic DNA probe indicated
in Fig. 1 detected a 4.6-kbHind III fragment and a 10.4-kb ScaI fragment
in the wild-type allele and an 8.4-kb HindIII fragment and a 6.5-kb ScaI
fragment in the mutant allele, respectively, indicating correct gene tar-
geting as outlined in Fig. 1. PCR analysis of the progeny of a typical
heterozygous Hrg+/– mating. (B) PCR detection of the disrupted allele
was accomplished with forward primer 1 (P1, see Fig. 1) derived from the
5¢ non-coding flanking region of the Hrg gene and with reverse primer 3
(P3), located in the neomycin cassette. Thus the PCR generates an
amplicon size of 2077 bp for the mutated allele. The PCR of the wild-type
allele with forward primer 1 and reverse primer 2 (P2) located within
the deleted region of the Hrg gene results in an amplicon size of 3091 bp.
Note that all three genotypes were represented in one progeny. DNA
marker (M) size in kb is indicated on the left.
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Figure 3.14: Confirmati n of Hrg gene knockout at t e level of gen mic DNA.
(A) Southern blot analysis of genomic DNA isolated from tail biopsies of Hrg+/+, Hrg+/- and Hrg-/- mice.
The genomic DNA probe indicated in figure 3.9 on page 40 detect d a 4.6-kb HindIII fragment and a
10.4-kb ScaI fragment in the wild-type allele and a 8.4-kb HindIII fragment and a 6.5-kb ScaI fragment
in themutant allele, respectively, indicating correct gene targeting as outlined in figure 3.9.
(B) PCR analysis of the progeny of a typical heterozygous (Hrg+/-)mating. PCR detection of the disrupted
allele was accomplished with forward primer 1 (P1, see figure 3.9) derived from the 5’ non-coding
flanking region of the Hrg g ne andwith r verse primer 3 (P3), locat d in the neomycin cassette. Thus
the PCR generates an amplicon size of 2077 bp for themutated allele. The PCR of the wild-type allele
with forward primer 1 and reverse primer 2 (P2) locatedwithin the deleted region of the Hrg gene results
in an amplicon size of 3099 bp. Note that all three genotypes were represented in one progeny. DNA
ma ker (M) size in kb is indicated on the left.
3.3.2 Hematological analysis
Tabelle 3.2 on page 47 lists the results of a routine hematology analysis using a cell counter. We
determined similar blood cell counts forHrg-/- mice and for wild-type mice with the exception
of o ocytes, which were 2.5-fold more abundant in HRG-deficient mice (5.3—3.0 %) than in
wild-type mice (2.1— 2.1 %, n=8, p=0.018). Routine indicated that the liver enzymes GOT/AST,
GPT/ALT, GGT, e renal function parameters urea and cr atinin as well as blood glucose,
triglycerides, and electrolytes were all normal in HRG-deficient and wild-type mice (Tabelle 3.3
on page 48) suggesting that liver, heart and kidney metabolism were not grossly compromised
by the lack of serumHRG. For a comparison of the parameter values see the mouse phenome
database – http://aretha.jax.org/pub-cgi/phenome/mpdcgi?rtn=docs/home – as reference.
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mice. Roughly half the amount of HRG protein could be
detected in serum from Hrg+/– mice compared to Hrg+/+
mice. This finding indicates that both copies of theHrg gene are
independently expressed. We obtained identical results when
we analyzed HRG levels in serum from the offspring of ES cell
clones 24 or 33 (Fig. 3), indicating that both strains represented
a true HRG null mutation at the serum protein level. Strain 33
was analyzed in more detail.
Hematological analysis
Routine hematology revealed similar blood cell counts for
Hrg–/– mice and for wild-type mice, but monocytes were
2.5-fold more abundant in HRG-deficient than in wild-type
mice (5.3 ± 3.0% vs. 2.1 ± 2.1%, n ¼ 8, P ¼ 0.018). Serum
activity GOT/AST, GPT/ALT, GGT, blood glucose, triglyc-
erides, urea, creatinine, and electrolytes were all normal in
HRG-deficient and wild-type mice suggesting that liver, heart
and kidney metabolism were uncompromised by the lack of
HRG (data not shown).
Blood coagulation
We estimated antithrombin activity using a chromogenic assay
measuring the residual activity of excess factor Xa in the
presence of a fixed amount of heparin. Commercial human
control plasmaN activity was set to 100% in this assay. Plasma
samples obtained from wild-type Hrg+/+ mice scored 107%
compared to human control plasma N. Plasma obtained from
heterozygous Hrg+/– mice had an elevated antithrombin
activity of 116% and HRG-deficient plasma from Hrg–/– mice
had an elevated antithrombin activity of 125%. The difference
in antithrombin activity betweenHrg+/+ andHrg–/– mice was
statistically highly significant (n ¼ 10 each, P ¼ 0.001, data
not shown).
We measured fibrinogen in plasma samples from male and
female mice (Fig. 4). The amount of fibrinogen was higher in
plasma from males than from females. This sex-specific
difference was 47% in wild-type mice (2.5 ± 0.4 g L)1 male,
1.7 ± 0.1 g L)1 female) to 35% in heterozygous Hrg+/– mice
(2.3 ± 0.3 g L)1 male, 1.7 ± 0.4 g L)1 female) and 13% in
Hrg–/– mice (2.6 ± 0.5 g L)1 male, 2.3 ± 0.4 g L)1 female).
Plasma fibrinogen was increased in HRG-deficient mice
compared to wild-type and Hrg+/– mice. This difference was
most pronounced in the plasma of HRG-deficient female mice,
containing 35% more fibrinogen (2.3 ± 0.4 g L)1) than
plasma from heterozygous and wild-type females (both 1.7 ±
0.1 g L)1).
Figure 5(A) illustrates that the prothrombin time was
significantly shorter in the plasma of HRG-deficient mice
(lane 4) than in human plasma (lane1), fetuin-A-deficient
(lane 2) or wild-type mouse plasma (lane 3), suggesting that
HRG deficiency was associated with faster extrinsic blood
clotting. This accelerated prothrombin time was specific for the
HRG deficiency, because deficiency in fetuin-A, a genetically –
but not functionally – related plasma protein, was not
associated with shortened prothrombin time. In addition,
reconstitution with purified human HRG of HRG-deficient
mouse plasma restored the prothrombin time to wild-type
levels (Fig. 5, lanes 4–7). Figure 5(B) depicts the immunoblot
analysis of the identical plasma samples analyzed in Fig. 5(A),
confirming that the clotting time increased with the amount of
HRG in the plasma samples.
Next we measured the bleeding time after amputation of a
5-mm length of tail tip as an in vivo parameter of combined
plasma and platelet mediated blood coagulation. The bleeding
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Fig. 3. Immunoblot analysis of serum Hrg expression. Serum (0.2 lL)
from progeny of a heterozygous F2 cross of clone 24 (A) or clone 33
(B) was separated by reducing SDS–PAGE and electrotransferred onto
nitrocellulose. HRG protein was detected by immunological staining
using rabbit polyclonal antibody raised against human HRG, peroxidase-
labeled secondary antibody and enhanced chemiluminescence detection.
+/+, wild-type; +/–, heterozygous; –/–, homozygous HRG-deficient;
hu, human serum. Note that no HRG was detected in Hrg–/– serum and
about half the amount of HRG was detected in serum from Hrg+/– mice
when compared to wild-type Hrg+/+ mice.
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Fig. 4. Fibrinogen concentration in plasma of wild-type and HRG-
deficient mice. +/+, wild-type; +/–, heterozygous; –/–, homozygous
HRG-deficient. Values represent the mean ±SD of 4–15 individual mice
as detailed in the figure. The P-values were calculated with Student’s t-test.
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Figure 3.15: Immunoblot analysis of serumHRG level.
Serum (0.2µL) from progeny of a heterozygous F2mating of clo e 24 (A) or clone 33 (B) was separated
by reducing SDS-PAGE and electrotransferred onto nitrocellulose. HRG protein was detected by im-
munological staining using rabbit polyclonal antibody raised against human HRG, peroxidase labeled
secondary antibody and enhanced chemiluminescence detection.+/+, wild-type; +/-, heterozygous;
-/-, homozygous HRG-deficien ; hu, h man serum. Note that no HRGwas detected in Hrg-/- serum and
about half the amount of HRGwas detected in seru fromHrg+/- mice when compared to wild-type
Hrg+/+ mice.
3.3.3 Blood coagulation factors
From several (mostly in vitro) studies HRG is known to interact with several factors involved in
blood coagulation and fibrinolysis. ´erefore antithrombin activity, fibrinogen level as well as the
prothrombin time in wild-type, heterozygous andHrg-/- mice were compared.
3.3.3.1 Antithrombin activity
To estimate antithrombin act vity the residual activity of excess fact r Xa in the presence of a fixed
amount of heparin was measured. ´is was performed with a chromogenic assay. Commercial
human control plasmaN activity was deliberately set to 100 % in this assay. Figure 3.16 on page 49
illustrates that plasma samples obtained from wild-typeHrg+/+ mice scored 107 % compared to
control plasma N. Plasma obtained from heterozygousHrg+/- mice had an elevated antithrombin
activity of 116 % and HRG-deficient plasma from Hrg-/- mice had an elevated antithrombin
activity of 125 %. ´e difference in antithrombin activity betweenHrg+/+ andHrg-/- mice was
statistically significant (n=10 each, p=0.001).
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Parameter Hrg+/+ (n = 8) Hrg-/- (n = 8)
Hemoglobin (g/dl) 13.4 — 0.3 13.6 — 0.7
Hematocrit (%) 53.3 — 1.1 55.8 — 3.6
WBC (×103/µl) 5.6 — 1.4 6.0 — 0.9
RBC (×106/µl) 10.0 — 0.3 10.4 — 0.4
Platelets (×103/µl) 812.5 — 100.6 727.5 — 203.2
MCV (µm3) 54.0 — 2.3 53.5 — 2.4
MCH (pg) 13.5 — 0.7 13.0 — 0.4
MCHC (g/dl) 25.1 — 0.4 24.4 — 0.9
Lymphocytes (%) 81.4 — 2.8 78.6 — 4.3
Monocytes (%) 2.1 — 2.1 5.3 — 3.0*
Band N 0.9 — 0.0 1.8 — 1.6
Seg N 14.9 — 3.9 13.4 — 3.0
Table 3.2: Routine hematological parameters.
Bloodwas collected by cardiac puncture and anticoagulated with EDTA. Values represent themean —
SEM of eight individual mice. Abbreviations: WBC, white blood cells; RBC, red blood cells; MCV, Mean
corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration; Band N, band neutrophils; seg N, segmented neutrophils. The number of mice analyzed
was n=8 in both genotypes.
3.3.3.2 Fibrinogen level
´e fibrinogen levels was measured according to the coagulometer method of Clauss (Clauss,
1957). ´e amount of fibrinogenwas higher in plasma samples ofHrg+/+ andHrg+/-males (2.5—0.4
g/l and 2.3—0.3 g/l, respectively) than in plasma of Hrg+/+ and Hrg+/- females (1.7—0.1 g/l and
1.7—0.4 g/l, respectively). ´is sex-specific difference was 47 % in wild-type mice (2.5—0.4 g/l male,
1.7—0.1 g/l female) to 35 % in heterozygous Hrg+/- mice (2.3—0.3 g/l male, 1.7—0.4 g/l female)
and 13 % in Hrg-/- mice (2.6—0.5 g/l male, 2.3—0.4 g/l female). Fibrinogen levels in plasma of
homozygous HRG-deficient males (2.6—0.5 g/l) and females (2.3—0.4 g/l) were both elevated
compared to wild-type and heterozygous animals of matched sex and age. ´is difference was
most pronounced in the plasma of the females. Plasma of HRG-deficient female mice had 35 %
more fibrinogen than plasma of heterozygous and wild-type females (figure 3.17 on page 50).
3.3.3.3 Prothrombin time
Figure 3.18 A on page 51 demonstrates that the prothrombin time was significantly shorter in
plasma of HRG-deficient mice (lane 4) than in human plasma (lane 1), fetuin-A-deficient (lane 2)
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Parameter Hrg+/+ (n = 7) Hrg-/- (n = 7)
GOT/AST (U/l) 40.5 — 11.5 30.8 — 5.7
GPT/ALT (U/l) 25 — 1.0 22.3 — 3.9
GGT (U/l) 4.0 — 0.0 4.0 — 0.0
Glucose (mmol/l) 5.7 — 0.7 8.8 — 0.8
Triglyceride (mmol/l) 1.2 — 0.2 1.3 — 0.3
Urea (mmol/l) 9.9 — 0.5 8.2 — 1.7
Creatinin (µmol/l) 21.0 — 2.0 20.2 — 0.7
Fe (µmol/l) 29.8 — 0.1 34.1 — 4.5
anorg. P (mmol/l) 2.4 — 0.2 2.6 — 0.2
Mg (mmol/l) 1.3 — 0.0 1.4 — 0.1
Na (mmol/l) 148.0 — 1.0 148.2 — 1.1
K (mmol/l) 4.8 — 0.1 6.0 — 0,5
Ca (mmol/l) 2.3 — 0.0 2.3 — 0.0
Table 3.3: Standard serum chemistry; Blood was collected by cardiac puncture.
After coagulation serum was obtained by centrifugation and stored by -80°C. Values repres-
ent the mean — SEM of 7 individual mice. Abbreviations: GOT/AST, glutamate-oxaloacetate-
transaminase/aspartate aminotransferase; GPT/ALT, glutamate-pyruvate-transaminase/alanine-
aminotransferase; GGT, gamma-glutamyl-transferase. Note that there were no significant differences
between wild-type and Hrg-/- mice in any of themeasuremed parameters.
or wild-type mouse plasma (lane 3), suggesting that HRG-deficieny was associated with faster
extrinsic blood clotting. ´is accelerated prothrombin time was specific for the HRG deficiency,
because deficiency in fetuin-A, a genetically- but not functionally- related plasma protein, was
not associated with shortened prothrombin time.
In addition, reconstitution with purified human HRG of HRG-deficient mouse plasma re-
stored the prothrombin time to wild-type levels (lanes 5-7). ´e immunoblot analysis of the
identical plasma samples (figure 3.18 B, lane 4-7) confirmed that the clotting time increased with
the amount of HRG in the plasma samples.
3.3.4 Effect on fibrinolysis of HRG
3.3.4.1 Whole blood clot lysis
Next we estimated the fibrinolytic activity in vena cava blood clotted by the addition of bovine
thrombin and 125I-labeled fibrinogen. Figure 3.19 A on page 52 illustrates that spontaneous clot
lysis was faster in HRG-deficient mice than in wild-type mice. Fieen minutes aer initiation of
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Figure 3.16: Antithrombin activity in plasma of wild-type, heterozygous and HRG-deficient mice.
Antithrombin activity wasmeasured in citrate plasma using a commercial kit. Antithrombin activity
of control plasma N in the presence of a fixed amount of heparin was deliberately set to 100%. Sub-
sequent measurements were calculated accordingly. Legends are +/+, wild-type; +/-, heterozygous
HRG-deficient; -/-, homozygous HRG-deficient. Values represent themean — SD of 10 individual mice
analyzed in each group. The p values were calculated with Student’s t-test.
blood clotting by the addition of thrombin we observed 4.36 — 0.24 % release of input radioactive
label into the soluble supernatant in blood fromHrg-/- mice vs. 1.30 — 0.10 % in wild-type mice.
´e accumulated release of 125I-labeled inHrg-/- and wild-type mice ranged from 8.74 — 0.31 %
vs. 2.66 — 0.23 % at 30 min, to 44.32 — 2.74 % vs. 14.90 — 0.23 % at 22.5 h. To visualize the
fibrin degradation peptides liberated during fibrinolysis we analyzed the lyzed clot supernatant
by SDS-PAGE and autoradiography (figure 3.19 B). In full accordance with the faster clot lysis in
Hrg-/- mice determined by radioacive measurement of clot lysis supernatants, higher amounts
of radioactive 125I-labeled fibrin degradation products were consistently detected in lyzed clot
supernatants of HRG-deficient mouse blood (figure 3.9 B on page 40, lane 5-8) than in lyzed clot
supernatants from wild-type mouse blood (lane 1-4). Taken together these results suggest that
HRGmay act as an antifibrinolytic in vivo.
3.3.5 Effect on Haemostasis: Bleeding TimeMeasurement
´e findings of a significantly shortened prothrombin time as well as the higher antithrombin
activity found in HRG-deficient mice point to an anticoagulatory activity of HRG.´erefore the
bleeding time aer amputation of a 5-mm length of tail tip as an in vivo parameter of combined
plasma and platelet mediated blood coagulation was measured. Measurements of the bleeding
time aer amputation revealed highly variable results ranging from 0.5 to 5.5 minutes (figure 3.20
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mice. Roughly half the amount of HRG protein could be
detected in serum from Hrg+/– mice compared to Hrg+/+
mice. This finding indicates that both copies of theHrg gene are
independently expressed. We obtained identical results when
we analyzed HRG levels in serum from the offspring of ES cell
clones 24 or 33 (Fig. 3), indicating that both strains represented
a true HRG null mutation at the serum protein level. Strain 33
was analyzed in more detail.
Hematological analysis
Routine hematology revealed similar blood cell counts for
Hrg–/– mice and for wild-type mice, but monocytes were
2.5-fold more abundant in HRG-deficient than in wild-type
mice (5.3 ± 3.0% vs. 2.1 ± 2.1%, n ¼ 8, P ¼ 0.018). Serum
activity GOT/AST, GPT/ALT, GGT, blood glucose, triglyc-
erides, urea, creatinine, and electrolytes were all normal in
HRG-deficient and wild-type mice suggesting that liver, heart
and kidney metabolism were uncompromised by the lack of
HRG (data not shown).
Blood coagulation
We estimated antithrombin activity using a chromogenic assay
measuring the residual activity of excess factor Xa in the
presence of a fixed amount of heparin. Commercial human
control plasmaN activity was set to 100% in this assay. Plasma
samples obtained from wild-type Hrg+/+ mice scored 107%
compared to human control plasma N. Plasma obtained from
heterozygous Hrg+/– mice had an elevated antithrombin
activity of 116% and HRG-deficient plasma from Hrg–/– mice
had an elevated antithrombin activity of 125%. The difference
in antithrombin activity betweenHrg+/+ andHrg–/– mice was
statistically highly significant (n ¼ 10 each, P ¼ 0.001, data
not shown).
We measured fibrinogen in plasma samples from male and
female mice (Fig. 4). The amount of fibrinogen was higher in
plasma from males than from females. This sex-specific
difference was 47% in wild-type mice (2.5 ± 0.4 g L)1 male,
1.7 ± 0.1 g L)1 female) to 35% in heterozygous Hrg+/– mice
(2.3 ± 0.3 g L)1 male, 1.7 ± 0.4 g L)1 female) and 13% in
Hrg–/– mice (2.6 ± 0.5 g L)1 male, 2.3 ± 0.4 g L)1 female).
Plasma fibrinogen was increased in HRG-deficient mice
compared to wild-type and Hrg+/– mice. This difference was
most pronounced in the plasma of HRG-deficient female mice,
containing 35% more fibrinogen (2.3 ± 0.4 g L)1) than
plasma from heterozygous and wild-type females (both 1.7 ±
0.1 g L)1).
Figure 5(A) illustrates that the prothrombin time was
significantly shorter in the plasma of HRG-deficient mice
(lane 4) than in human plasma (lane1), fetuin-A-deficient
(lane 2) or wild-type mouse plasma (lane 3), suggesting that
HRG deficiency was associated with faster extrinsic blood
clotting. This accelerated prothrombin time was specific for the
HRG deficiency, because deficiency in fetuin-A, a genetically –
but not functionally – related plasma protein, was not
associated with shortened prothrombin time. In addition,
reconstitution with purified human HRG of HRG-deficient
mouse plasma restored the prothrombin time to wild-type
levels (Fig. 5, lanes 4–7). Figure 5(B) depicts the immunoblot
analysis of the identical plasma samples analyzed in Fig. 5(A),
confirming that the clotting time increased with the amount of
HRG in the plasma samples.
Next we measured the bleeding time after amputation of a
5-mm length of tail tip as an in vivo parameter of combined
plasma and platelet mediated blood coagulation. The bleeding
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Fig. 3. Immunoblot analysis of serum Hrg expression. Serum (0.2 lL)
from progeny of a heterozygous F2 cross of clone 24 (A) or clone 33
(B) was separated by reducing SDS–PAGE and electrotransferred onto
nitrocellulose. HRG protein was detected by immunological staining
using rabbit polyclonal antibody raised against human HRG, peroxidase-
labeled secondary antibody and enhanced chemiluminescence detection.
+/+, wild-type; +/–, heterozygous; –/–, homozygous HRG-deficient;
hu, human serum. Note that no HRG was detected in Hrg–/– serum and
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Fig. 4. Fibrinogen concentration in plasma of wild-type and HRG-
deficient mice. +/+, wild-type; +/–, heterozygous; –/–, homozygous
HRG-deficient. Values represent the mean ±SD of 4–15 individual mice
as detailed in the figure. The P-values were calculated with Student’s t-test.
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Figure 3.17: Fibrinogen concentration in plasma of wild-type and HRG-deficient mice.
Plasmawas harvested by cardiac puncture and anti-coagulated with citrate. Fibrinogen was determ-
ined in +/+, wild-type; +/-, heterozygous HRG-deficient; -/-, homozygous HRG-deficientmice using a
commercial kit. Values represent themean — SD of 4-15 individual mice as detailed in the figure. The
p-values were calculated with Student’s t-test.
on page 53), Nevertheless, the bleeding time was significantly shorter inHrg-/- mice compared to
Hrg+/+ mice (median — SEM, 50 — 8s, n = 14 vs. 62 — 22s, n =23, p < 0.01). Hrg+/- mice showed
bleeding times similar to wild-type mice (63 — 10s, n = 27).
Taken together the results frommeasurements of prothrombin time and bleeding time suggest
a mild, yet statistically significant, anticoagulant action of plasma HRG. However, HRG may
compete with antithrombin through binding to heparin as a result of antithrombin activity
measurement, suggesting procoagulant act of HRG.´emechanism of these modulation act of
HRG is not elucidated.
3.3.6 Skin woundmodel
To evaluate if the observed differences in both coagulation and fibrinolysis would influence the
healing of an external w und, which involves both hrombosis and fibrinolysis, we inflicted
f ll thickness skin wounds to the back of Hrg-/- and wild-type mice. ´e examination of the
wound healing was done mainly by Dr. Silke Ensslen. One day aer excision of skin biopsies
the wounds had shrunk to about 50 % of the original wounded area in both wild-type andHrg-/-
mice. ´e wounds were typically covered by a dry eschar within 2 days (not shown). A detailed
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times were highly variable, ranging from 0.5 to 5.5 min
(Fig. 6). Nevertheless, the bleeding time was significantly
shorter in Hrg–/– mice compared to Hrg+/+ mice (median
±SEM, 50 ± 8 s, n ¼ 14 vs. 62 ± 22 s, n ¼ 23, P < 0.01).
Hrg+/– mice showed bleeding times similar to wild-type mice
(63 ± 10 s, n ¼ 27).
Taken together the results frommeasurements of antithrom-
bin activity, prothrombin time and bleeding time suggest a
mild, yet statistically significant, anticoagulant action of plasma
HRG.
Next we estimated the fibrinolytic activity in vena cava blood
clotted by the addition of bovine thrombin and 125I-labeled
fibrinogen. Figure 7(A) illustrates that spontaneous clot lysis
was faster in HRG-deficient mice than in wild-type mice.
Fifteenminutes after initiation of blood clotting by the addition
of thrombin we observed 4.36 ± 0.24% release of input
radioactive label into the soluble supernatant in blood from
Hrg–/– mice vs. 1.30 ± 0.10% in wild-type mice. The accu-
mulated release of 125I label in Hrg–/– and wild-type mice
ranged from 8.74 ± 0.31% vs. 2.66 ± 0.23% at 30 min, to
44.32 ± 2.74% vs. 14.90 ± 0.23% at 22.5 h. To visualize the
fibrin degradation peptides liberated during fibrinolysis we
analyzed the lyzed clot supernatant by SDS–PAGE and
autoradiography (Fig. 7B). In full accordance with the faster
clot lysis in Hrg–/– mice determined by radioactive measure-
ment of clot lysis supernatants, higher amounts of radioactive
125I-labeled fibrin degradation peptides were consistently
detected in lyzed clot supernatants of HRG-deficient mouse
blood (Fig. 7B, lane 5–8) than in lyzed clot supernatants from
wild-type mouse blood (lane 1–4). Taken together these results
suggest that HRG may act as an antifibrinolytic in vivo.
Skin wound model
To evaluate if the observed differences in both coagulation and
fibrinolysis would influence the healing of an external wound,
which involves both thrombosis and fibrinolysis, we inflicted
full thickness skin wounds to the back ofHrg–/– and wild-type
mice. One day after excision of skin biopsies the wounds had
shrunk to about 50% of the original wounded area in both
wild-type andHrg–/– mice. The wounds were typically covered
by a dry eschar within 2 days (not shown). A detailed
morphometric analysis of the wound healing was performed
using electronic images of the wounds. Large variation of
wound areas existed within experimental groups during the
wound contraction period (day 1–4) regardless of their
genotype. These differences leveled out during the first week.
We did not observe statistically significant differences in the
gross morphology (not shown) and timing of wound healing
between wild-type and Hrg–/– mice indicating that the pertur-
bation of plasmatic and platelet-mediated blood clotting
observed ex vivo did not overtly influence the wound healing
in this simple wounding model (data not shown).
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Fig. 5. Prothrombin time measurement in human and mouse plasma.
(A) Prothrombin time was measured using a coagulometer. (B) Immu-
noblot analysis of the plasma samples used in (A). Lane 1, human plasma;
lane 2, mouse fetuin-A-deficient plasma; lane 3, wild-type plasma; lane 4,
HRG-deficient plasma; lanes 5–7, HRG-deficient plasma with 10, 30
and 60 lg mL)1 human HRG added, respectively. Note that the recon-
stitutionwith humanHRG (60 lg mL)1) ofHRG-deficientmouse plasma
restored normal prothrombin time dose-dependently. Values represent
the mean±SD of four individual mice. TheP-values were calculated with
Student’s t-test.
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Fig. 6. Bleeding time. Tail tips were clipped and the bleeding time was
determined as described in the Materials and methods. Data are displayed
in a box plot of the indicated number of individual measurements for
each genotype. Each box encloses 50% of the data with the median value
of the variable displayed as a line. The top and bottom of the box mark
the limits of ±25% of the variable population. The lines extending
from the top and bottom of each box mark the minimum and maximum
values within the data set that fall within an acceptable range. Any
value outside this range, called an outlier, is displayed as an individual
point. Outliers are included in all calculations. P-values of Student’s t-tests
are indicated at the top of the columns.
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Figure 3.18: Prothrombin ti e measurement in human andmouse plasma.
(A) Prothrombin time wasmeasured using a coagulometer.
(B)HRG immunoblot analysis of the plasma samples used in (A). Lane 1, human plasma; lane 2, mouse
fetuin-A-deficient plasma; lane 3, wild-type plasma; lane 4, HRG-deficient plasma; lanes 5-7, HRG-
deficient plasmawith 10, 30 and 60 µg/mLhumanHRGadded, respectively. Note th t the reconstitution
with human HRG (60 µg/mL) of HRG-deficie ouse plasma restored no mal prothrombin time dose-
dependently. Values represent themean — SD of four individual mice in each group. The p values were
calculated with Student’s t-test.
morphometric analysis of the wound healing was performed using electronic images of the
wounds. Large variation of wound areas existed within experimental groups during the wound
contraction period (day 1-4) regardless of their genotype. ´ese differences leveled out during
the first week. We did not observe statistically sig ificant differences in the gross morphology
and timing of wound healing between wild-type andHrg-/- mice indicating that the perturbation
of plasmatic and platelet-mediated blood clotting observed ex vivo did not overtly influence the
wound healing in this simple wounding model.
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Discussion
To analyze the physiological function of HRG we generated
HRG-deficient mice by deleting the translation start point of
exon 1 of the gene through homologous recombination. The
Hrg null mutants had no immunologically detectable HRG
protein in their plasma and the mice were fertile. We
successfully bred homozygous HRG-deficient mice for several
generations. These data indicate that HRG is dispensable
during normal embryogenesis and development.
Homozygous HRG-deficient mice had significantly higher
numbers of monocytes in their blood than wild-type mice. At
present we have no explanation for this mild monocytosis.
Recently HRG was described as a potent opsonin [30] and we
speculate that the lack of HRG could trigger monocyte
proliferation to compensate for a potential decrease in phago-
cyte activation. A thorough investigation of the innate immune
response in HRG-deficient mice will clarify the potential
immune modulatory contribution of HRG.
A role of HRG in hemostasis has been repeatedly proposed
based on the observation that HRG binds several components
of the coagulation and fibrinolysis cascades. Prothrombin time
was significantly shorter in Hrg–/– plasma samples than in
Hrg+/+ samples, and reconstitution of the plasma samples
with purified human HRG normalized the prothrombin time.
Hence we conclude that HRG may regulate the extrinsic
pathway of coagulation in mice by interacting with thrombin.
Our observation that HRG-deficient plasma also had higher
antithrombin activity suggests an additional and alternative
mechanism of HRG anticoagulant activity. Antithrombin is a
potent physiological negative regulator of the blood coagula-
tion inhibiting thrombin, factor Xa and factor IXa [31]. Its
inhibitory activity towards serine proteases is much enhanced
in the presence of heparin [32]. HRGhas a high binding affinity
for heparin and therefore potentially competes with the binding
of heparin to antithrombin [33]. Consequently, HRG inhibits
the high-affinity binding of antithrombin to thrombin as well as
the antifactor Xa activity of antithrombin. Therefore, HRG is
considered a modulator of anticoagulant activity of heparin in
human plasma [34]. Comparing unmodified plasma samples of
HRG-deficient mice and wild-type mice, we determined that
HRG can antagonize antithrombin activity in vivo.
It is known that HRG interacts with fibrinogen in vitro [9].
HRG-deficient mice of both sexes had elevated plasma
fibrinogen, especially female Hrg–/– mice, which had 35%
more plasma fibrinogen than age- and sex-matched wild-type
mice. This is the first demonstration in vivo that HRG levels in
blood might also influence the level of the most abundant
protein of the blood coagulation cascade, possibly associated
with enhanced plasma coagulation. Similar observations exist
in human patients. Three cases of congenital HRG deficiency
have been reported to date [10–12]. Strikingly, all patients
suffering from embolism were women. One patient with the
HRG Tokushima 2 allele had only 50% of the normal HRG
plasma level, and had associated elevated fibrinogen [12]. Given
the shorter prothrombin time and the elevated fibrinogen levels
one may ask, why a thrombophilic phenotype was not
observed in HRG-deficient mice. One should recall at this
point that HRG binds to plasminogen in plasma and is
supposed to act as an antifibrinolytic [7]. Therefore the lack of
HRG should be associated with faster fibrinolysis, which was
indeed confirmed by measurements in Hrg–/– blood. This
finding is compatible with a report that poly-histidine a
surrogate of the histidine-rich region of HRG down-regulated
fibrinolysis by suppressing plasmin interaction with fibrin [35].
Recently it was suggested that HRG mediated high-affinity
tethering of plasminogen to cell surfaces, thus activating
fibrinolyis [16]. This does not exclude the enhanced fibrinolysis
observed in plasma of HRG-deficient mice, because the HRG
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Fig. 7. Fibrinolytic activity in clotted mouse blood. Mouse blood was
diluted with saline and clotted by the addition of Ca2+ and bovine
thrombin using 125I-labeled fibrinogen as a tracer. Fibrinolysis was
measured as the release of 125I radioactivity into the soluble clot super-
natant. (A) Data represent the mean ±SEM of accumulated blood clot
lysis of Hrg+/+ (j, n ¼ 6) and Hrg–/– (s, n ¼ 6) mice expressed as
percent of radioactivity of 125I-labeled fibrinogen recovered in the lyzed
clot supernatant. (B) Ten-microliter aliquots of lyzed clot supernatant
harvested after 15, 30, 60 and 90 min of spontaneous clot lysis were
separated on SDS–PAGE and autoradiographed. Lanes 1 and 5, 15 min;
lanes 2 and 6, 30 min; lanes 3 and 7, 1 h; lane 4 and 8, 1.5 h. Note the
abundance of fibrin degradation products in HRG-deficient clot super-
natants (lanes 5–8) compared to wild-type clot supernatants (lanes 1–4).
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Discussion
To analyze the physiological function of HRG we generated
HRG-deficient mice by deleting the translation start point of
exon 1 of the gene through homologous recombination. The
Hrg null mutants had no immunologically detectable HRG
protein in their plasma and the mice were fertile. We
successfully bred homozygous HRG-deficient mice for several
generations. These data indicate that HRG is dispensable
during normal embryogenesis and development.
Homozygous HRG-deficient mice had significantly higher
numbers of monocytes in their blood than wild-type mice. At
present we have no explanation for this mild monocytosis.
Recently HRG was described as a potent opsonin [30] and we
speculate that the lack of HRG could trigger monocyte
proliferation to compensate for a potential decrease in phago-
cyte activation. A thorough investigation of the innate immune
response in HRG-deficient mice will clarify the potential
immune modulatory contribution of HRG.
A role of HRG in hemostasis has been repeatedly proposed
based on the observation that HRG binds several components
of the coagulation and fibrinolysis cascades. Prothrombin time
was significantly shorter in Hrg–/– plasma samples than in
Hrg+/+ samples, and reconstitution of the plasma samples
with purified human HRG normalized the prothrombin time.
Hence we conclude that HRG may regulate the extrinsic
pathway of coagulation in mice by interacting with thrombin.
Our observation that HRG-deficient plasma also had higher
antithrombin activity suggests an additional and alternative
mechanism of HRG anticoagulant activity. Antithrombin is a
potent physiological negative regulator of the blood coagula-
tion inhibiting thrombin, factor Xa and factor IXa [31]. Its
inhibitory activity towards serine proteases is much enhanced
in the presence of heparin [32]. HRGhas a high binding affinity
for heparin and therefore potentially competes with the binding
of heparin to antithrombin [33]. Consequently, HRG inhibits
the high-affinity binding of antithrombin to thrombin as well as
the antifactor Xa activity of antithrombin. Therefore, HRG is
considered a modulator of anticoagulant activity of heparin in
human plasma [34]. Comparing unmodified plasma samples of
HRG-deficient mice and wild-type mice, we determined that
HRG can antagonize antithrombin activity in vivo.
It is known that HRG interacts with fibrinogen in vitro [9].
HRG-deficient mice of both sexes had elevated plasma
fibrinogen, especially female Hrg–/– mice, which had 35%
more plasma fibrinogen than age- and sex-matched wild-type
mice. This is the first demonstration in vivo that HRG levels in
blood might also influence the level of the most abundant
protein of the blood coagulation cascade, possibly associated
with enhanced plasma coagulation. Similar observations exist
in human patients. Three cases of congenital HRG deficiency
have been reported to date [10–12]. Strikingly, all patients
suffering from embolism were women. One patient with the
HRG Tokushima 2 allele had only 50% of the normal HRG
plasma level, and had associated elevated fibrinogen [12]. Given
the shorter prothrombin time and the elevated fibrinogen levels
one may ask, why a thrombophilic phenotype was not
observed in HRG-deficient mice. One should recall at this
point that HRG binds to plasminogen in plasma and is
supposed to act as an antifibrinolytic [7]. Therefore the lack of
HRG should be associated with faster fibrinolysis, which was
indeed confirmed by measurements in Hrg–/– blood. This
finding is compatible with a report that poly-histidine a
surrogate of the histidine-rich region of HRG down-regulated
fibrinolysis by suppressing plasmin interaction with fibrin [35].
Recently it was suggested that HRG mediated high-affinity
tethering of plasminogen to cell surfaces, thus activating
fibrinolyis [16]. This does not exclude the enhanced fibrinolysis
observed in plasma of HRG-deficient mice, because the HRG
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Fig. 7. Fibrinolytic activity in clotted mouse blood. Mouse blood was
diluted with saline and clotted by the addition of Ca2+ and bovine
thrombin using 125I-labeled fibrinogen as a tracer. Fibrinolysis was
measured as the release of 125I radioactivity into the soluble clot super-
natant. (A) Data represent the mean ±SEM of accumulated blood clot
lysis of Hrg+/+ (j, n ¼ 6) and Hrg–/– (s, n ¼ 6) mice expressed as
percent of radioactivity of 125I-labeled fibrinogen recovered in the lyzed
clot supernatant. (B) Ten-microliter aliquots of lyzed clot supernat nt
harvested after 15, 30, 60 and 90 min of spontaneous clot lysis were
separated on SDS–PAGE and autoradiographed. Lanes 1 and 5, 15 min;
lanes 2 and 6, 30 min; lanes 3 and 7, 1 h; lane 4 and 8, 1.5 h. Note the
abundance of fibrin degradation products in HRG-deficient clot super-
natants (lanes 5–8) compared to wild-type clot supernatants (lanes 1–4).
870 N. Tsuchida-Straeten et al
! 2005 International Society on Thrombosis and Haemostasis
Figure 3. : (A) Fibrinolytic activity in clottedmouse bl od. Mouse blood was diluted wi h salin a
clottedby theadditionof Ca2+ andbovine thrombinusing 125I-labeledfibrinogenasa tracer. Fibrinolysis
wasmeasured as the release of 125I radioactivity into the soluble clot supernatant. (A) Data represent
themean — SEM of accumulated blood clot lysis of Hrg+/+ (ν, = 6) and Hrg-/- (µ, n = 6) mice expr ssed
as percent of radioactivity of 125I-labeled fibrinogen recovered in t e lyzed clot supernatant.
(B)Fibrinolyticanalysis byNuPage™ gel electrophoresis. Tenmicroliter aliquotsof lyzedclot supernatant
harvested after 15, 30, 60 and 90 min of spontaneous clot lysis were separated on SDS-PAGE and
autoradiographed. Lanes 1 and 5, 15 min; lane 2 and 6, 30 min; lanes 3 nd 7, 1h; lane 4 and 8, 1.5
h. Note the abundance of fibrin degradation products in HRG- eficient clot supernatants (lane 5-8)
compared to wild-type clot supernatants (lanes 1-4).
3.3.7 Influence of HRG on plat le fu ction
3.3.7.1 Platelet aggregation activity
To determine the effect of HRG deficiency on platelet fuction in vitro, platelet aggregation activity
of platelet-rich plasma from wiltype andHrg-/- mice was measured (figure 3.21 on page 54). Plate-
lets play a key role not only in physiological hemostasis, bu also u der pathological conditions
such as thrombosis. Upon bl od vessel injury, the endothelial layer is damaged and platelets can
interact with subendothelial adhesive proteins as vonWillebrand factor and collagen. Histidine-
rich glycoprotein is known to bind to activated platelets, mediated by transition metals (Horne
et al., 2001; Lerch et al., 1988). Platelet activation was in tiated by collagen, thrombin and ADP
as agonist (figure 3.21). C llagen and thr mbin are strong agonists which induce massive ADP
release from dense granules, where it occurs in molar concentrations. ´us, the action of ADP
(which is a weak agonist per/se) underlies a positive feedback that facilitates further platelet
aggregation and lead to platelet plug formation. Aggregation responses to collagen (A), thrombin
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times were highly variable, ranging from 0.5 to 5.5 min
(Fig. 6). Nevertheless, the bleeding time was significantly
shorter in Hrg–/– mice compared to Hrg+/+ mice (median
±SEM, 50 ± 8 s, n ¼ 14 vs. 62 ± 22 s, n ¼ 23, P < 0.01).
Hrg+/– mice showed bleeding times similar to wild-type mice
(63 ± 10 s, n ¼ 27).
Taken together the results frommeasurements of antithrom-
bin activity, prothrombin time and bleeding time suggest a
mild, yet statistically significant, anticoagulant action of plasma
HRG.
Next we estimated the fibrinolytic activity in vena cava blood
clotted by the addition of bovine thrombin and 125I-labeled
fibrinogen. Figure 7(A) illustrates that spontaneous clot lysis
was faster in HRG-deficient mice than in wild-type mice.
Fifteenminutes after initiation of blood clotting by the addition
of thrombin we observed 4.36 ± 0.24% release of input
radioactive label into the soluble supernatant in blood from
Hrg–/– mice vs. 1.30 ± 0.10% in wild-type mice. The accu-
mulated release of 125I label in Hrg–/– and wild-type mice
ranged from 8.74 ± 0.31% vs. 2.66 ± 0.23% at 30 min, to
44.32 ± 2.74% vs. 14.90 ± 0.23% at 22.5 h. To visualize the
fibrin degradation peptides liberated during fibrinolysis we
analyzed the lyzed clot supernatant by SDS–PAGE and
autoradiography (Fig. 7B). In full accordance with the faster
clot lysis in Hrg–/– mice determined by radioactive measure-
ment of clot lysis supernatants, higher amounts of radioactive
125I-labeled fibrin degradation peptides were consistently
detected in lyzed clot supernatants of HRG-deficient mouse
blood (Fig. 7B, lane 5–8) than in lyzed clot supernatants from
wild-type mouse blood (lane 1–4). Taken together these results
suggest that HRG may act as an antifibrinolytic in vivo.
Skin wound model
To evaluate if the observed differences in both coagulation and
fibrinolysis would influence the healing of an external wound,
which involves both thrombosis and fibrinolysis, we inflicted
full thickness skin wounds to the back ofHrg–/– and wild-type
mice. One day after excision of skin biopsies the wounds had
shrunk to about 50% of the original wounded area in both
wild-type andHrg–/– mice. The wounds were typically covered
by a dry eschar within 2 days (not shown). A detailed
morphometric analysis of the wound healing was performed
using electronic images of the wounds. Large variation of
wound areas existed within experimental groups during the
wound contraction period (day 1–4) regardless of their
genotype. These differences leveled out during the first week.
We did not observe statistically significant differences in the
gross morphology (not shown) and timing of wound healing
between wild-type and Hrg–/– mice indicating that the pertur-
bation of plasmatic and platelet-mediated blood clotting
observed ex vivo did not overtly influence the wound healing
in this simple wounding model (data not shown).
14
A
B
p = 0.08
p = 0.01
p = 0.0003
p = 0.0002
13
12
11
10
9
pr
ot
hr
om
bi
n 
tim
e 
[s]
8
1
kDa
94
67
43
30
2 3 4 5 6 7
Fig. 5. Prothrombin time measurement in human and mouse plasma.
(A) Prothrombin time was measured using a coagulometer. (B) Immu-
noblot analysis of the plasma samples used in (A). Lane 1, human plasma;
lane 2, mouse fetuin-A-deficient plasma; lane 3, wild-type plasma; lane 4,
HRG-deficient plasma; lanes 5–7, HRG-deficient plasma with 10, 30
and 60 lg mL)1 human HRG added, respectively. Note that the recon-
stitutionwith humanHRG (60 lg mL)1) ofHRG-deficientmouse plasma
restored normal prothrombin time dose-dependently. Values represent
the mean±SD of four individual mice. TheP-values were calculated with
Student’s t-test.
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Fig. 6. Bleeding time. Tail tips were clipped and the bleeding time was
determined as described in the Materials and methods. Data are displayed
in a box plot of the indicated number of individual measurements for
each genotype. Each box encloses 50% of the data with the median value
of the variable displayed as a line. The top and bottom of the box mark
the limits of ±25% of the variable population. The lines extending
from the top and bottom of each box mark the minimum and maximum
values within the data set that fall within an acceptable range. Any
value outside this range, called an outlier, is displayed as an individual
point. Outliers are included in all calculations. P-values of Student’s t-tests
are indicated at the top of the columns.
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Figure 3.20: Bleeding Time.
Tail tips were clipped and the bleeding timewas determined as described in theMaterials andMethods.
Data are displayed in a box plot of the indicated number of i ividualmeasurements for each genotype.
Each box encloses 50% of the data with themedian va ue of the variable displayed as a line. The top
and bottom of the boxmark the limits of — 25% of the variable pop lation. The lines extending from
the top and bottom of each boxmark theminimum andmaximum values within the data set that fall
within an acceptable range. Any value outside this range, called an outlier, is displayed as an individual
point. Outliers are included in all calculations. P- values of Student’s t-test are indicated at the top of the
column .
(B) and ADP (C) are significantly enhanced in Hrg-/- mice compared to wild-type mice with
the highest response measured aer thrombin stimulation. As suggested the lowest activation
was determined with the weak agonist ADP.´ese results suggest that HRGmay function as an
anti-platelet aggregation factor.
´e platelet aggregation activity measured with washed platelets aer stimulation with ADP
and collagen resulted in no significant differences betweenHrg+/+ andHrg-/- platelets (data not
shown).
3.3.7.2 Immunoblot analysis of platelet HRG
Nevertheless HRG was detectable in washed platelets isolated from wild-type mice (figure 3.22
on the following page). ´e immunoblot analysis of electrophoretically separated platelet protein
reveal d two bands c aract ristic of HRG (one 80 kDa band and a major pro eolytic degradation
product of about 70 kDa) as seen in serum samples. No band was detected in platelet samples of
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Figure 3.21: Representative tracing of the platelet aggregation to collagen, thrombin and ADP in
platelet rich plasma (PRP) fromHrg-/-(129/B6), Hrg-/-(B6) andwild-type (129/B6) mice in vitro.
Platelet count was adjusted to 350×103/µl by diluting PRP with platelet poor plasma and samples
were evaluated for in vitro platelet function in an automated aggregometer. Aggregation responses to
20µg/ml of collagen (A), 0.15U thrombin (B) and 20µMADP (C) are significantly enhanced in Hrg-/- mice.
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Figure 3.22: Platelets (175×104) of wild-type and HRG-deficient mice were washed and lyzed.
Platelet protein was reduced, separated by SDS-PAGE and blotted onto a nitrocellulose membrane.
HRG protein was detected by immunological staining using rabbit polyclonal antibody raised against
human HRG, peroxidase-labeled secondary antibody and enhanced chemiluminscence detection.
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4.1 Structural characterization of themurine histidine-rich
glycoprotein gene
I have cloned Hrg gene fragments from a mouse strain 129/SvJ genomic phage library and a
RPCI21 mouse PAC library, and determined their nucleotide sequences (figure 3.5). ´e mouse
Hrg gene is composed of 7 exons and 6 introns (see figure 3.5 on page 36) like the humanHRG gene,
and all exon-intron boundaries match the consensus GT/AG sequence for donor and acceptor
splice sites (figure 3.22 on the facing page).
                   Exon                  Intron                   Exon
   
   HUMAN        GAC AGA GTG  GTGAGGAA  -(A,2721 bp)-  TTCCTCAG GAA AAT ACA
           1    Asp Arg Val                                    Glu Asn Thr 
   MOUSE        GAG AGA GCC  GTAAGACT  -(A,2315 bp)-  TCCCTTAG GGA ACG GCC
                Glu Arg Ala                                    Gly Thr Ala
   HUMAN        TCT GAA ATA  GTAAGTAAA -(B,886 bp)- TTTCTTACAG GTG ATC GGA 
           2    Ser Glu Ile                                    Val Ile Gly
   MOUSE        TCT GAA ATA  GTAAGTAACG-(B,677 bp)- TCTTTTACA  GTG ATT GGA
                Ser Glu Ile                                    Val Ile Gly
   HUMAN        AGT TCT G    GTATGGTAAT-(C,1593 bp)-CTTTCTCCAG  TC TCT TCA
           3    Ser Ser Val                                    Val Ser Ser
   MOUSE        CAA GTT CTG  GTAAGGTCAT-(C,1504 bp)-CTTCCTCTAG TCT CTT CAG
                Gln Val Leu                                    Ser Leu Gln
   HUMAN        GCA AGA GTG  GTGAGTCTCC-(D,996 bp) -TCTGTTCTAG AGA GGA GGG
           4    Ala Arg Val                                    Arg Gly Gly
   MOUSE        ATA AGA GCG  GTGAGTTCCC-(D,1260 bp)-TCTGTTCTAG AGA GGA GGG
                Ile Arg Ala                                    Arg Gly Gly
   HUMAN        CAC CCC AAT  GTGAGTATAA-(E,2221 bp)-TCCTTTGTAG GTC TTT GGA
           5    His Pro Asn                                    Val Phe Gly
   MOUSE        TCC CCT CTG  GTAAGTAGTGT-(E,1613bp)-CCCTTTGAAG GTC TTT GGA
                Ser Pro Leu                                    Val Phe Gly
   HUMAN        GAC CCT CAG  GTGGGTTGTC-(F,1853 bp)-CCTTTTCCAG GAA CAT GAG
           6    Asp Pro Gln                                    Glu His Glu
   MOUSE        AAC ATT GAG  GTGGGTTTGA-(F,1476 bp)-CCTTTACCAG GAT CAT AAA
                Asn Asn Ile                                    Asp His Lys
      consensus     (C/A)AG  GT(A/G)AGT     (T/C)(T/C)N(T/C)AG G
  
Ser Ser Val Val S r Ser
Ile G u
Figure 4.1: Exon-intron boundary sequences of human andmouse Hrg genes.
Nucleotide sequences, whichmatch the consensus GT/AG sequence for donor and acceptor splice sites
are depicted by blue letters.
´e comparison of the gene structure of humanHRG andmouseHrg indicates that the length
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of the exons are well conserved, but the length and sequence of introns are variable (figure 4.2).
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Figure 4.2: Comparison of the structure for human andmouse Hrg gene.
The red boxes indicate exons I-VII whereas introns are given by the characters A-F. Additionally the
length of all exons and introns are shown.
4.1.1 Predicted promoter binding sequence
Sequence comparison of the promoter regions of mouse and human HRG genes revealed an
extensive sequence similarity position of the human nucleotide sequence to the transcription
start point (figure 3.8 on page 39). ´is region may involve a critical sequence to regulateHrg
gene expression for mouse and human. Many potential transcription factor recognition sites
in the 5’-flanking region of the mouse Hrg gene were found by computer searching, although
the TATA sequence was absent in the mouse Hrg gene. It was suggested for the human HRG
gene that the sequence between -262 and -21 from the translation initiation site promotes the
liver-specific transcription (Wakabayashi et al., 1999) and the region from -164 to -77 is essential
for the expression (unpublished results).
´e sequence of this region is well conserved between themouse and humanHRG gene. Since
it is known that human andmouse HRG is synthesized in liver and expressed only in hepatocytes,
transcription factors such as hepatic nuclear factor-1 (HNF-1C), hepatocyte-specific transcrip-
tional activator and C/EBP like enhancing- binding proteins (C/EBP) may play critical roles in
mouseHrg gene expression. ´ese factors are defined as hepatic enriched nuclear transcriptional
activators. Further studies will reveal the contribution of each transcription factor.
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4.2 Analysis of HRG-deficient mice
To analyze the physiological function of HRG we generated HRG-deficient mice by deleting
the translation start point of exon I of the gene through homologous recombination. ´e HRG
null mutants contained no immunologically detectable HRG in their plasma. Nevertheless, the
mice were fertile and appeared healthy, with no gross abnormalities observed upon macroscopic
inspection or in serum chemistry.
We successfully bred homozygous HRG-deficient mice for several generations. Post-natal
the mice developed normally and reached adulthood as in the case of the targeted deletion of
the related fetuin-A (Jahnen-Dechent et al., 1997). ´ree-month mortality was normal at 2.6 %
compared to wild-type mice. ´ese results indicate that HRG is not essential for development
and growth to sexual maturity.
4.2.1 Effect of HRG on hematology
Published literature suggests that HRG is a regulator of thrombosis and hemostasis and therefore
we performed routine hematology analysis. Individual blood samples did not show major dif-
ferences between homozygous and wild-type mice, with one notable exception. Homozygous
HRG-deficient mice had significantly higher numbers of monocytes in their blood than wild-type
mice.
At present we have no explanation for this mild monocytosis. Recently, however, HRG was
described as a potent opsonin (Gorgani et al., 2002) and we speculate that the lack of HRG could
trigger monocyte proliferation to compensate for a potential decrease in phagocyte activation. A
thorough investigation of the innate immune response in HRG-deficient mice will clarify this
potential immune modulatory contribution of HRG.
4.2.2 Effect of HRG on blood coagulation system
A role of HRG in hemostasis has been repeatedly proposed based on the observation that HRG
binds several components of the coagulation and fibrinolysis cascades (see section 1.2.1 on
page 12). Supporting this view we determined that plasma samples revealed modest, but stat-
istically significant differences in routine coagulation parameters when plasma samples from
HRG-deficient and wild-type mice were compared.
4.2.2.1 Effect of HRG on Prothrombin time
Measurement of prothrombin time in citrate plasma can reveal disorders in clotting factors II,
V, VII and X, all of which belong to the extrinsic blood coagulation pathway. Prothrombin time
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was significantly shorter inHrg-/- plasma samples than inHrg+/+ and in human plasma samples.
Addition of purified human HRG to plasma samples of HRG-deficient-mice normalized the
prothrombin time, dose-dependently. Human HRG strongly interacts with thrombin in a zinc-
dependent manner [Ohnishi, Koide et al., unpublished result]. Hence we conclude that HRGmay
regulate the extrinsic pathway of coagulation in mice by interacting with thrombin.
4.2.2.2 Effect of HRG on Antithrombin activity
Our observation that HRG-deficient plasma also had higher anthithrombin activity suggests
an additional and alternative mechanism of HRG anticoagulant activity. Antithrombin is the
most potent physiological negative regulator of the blood coagulation inhibiting thrombin, factor
Xa and factor IXa (Davie and H., 1977). Its inhibitory activity towards serine proteases is much
enhanced in the presence of heparin (Rosenberg, 1975). HRG has a high binding affinity for
heparin and therefore potentially competes with the binding of heparin to antithrombin (Lijnen
et al., 1983a). Consequently, HRG inhibits the high-affinity binding of antithrombin to thrombin
as well as the anti-factor Xa activity of antithrombin (Lijnen et al., 1983b).
´erefore, HRG is considered a modulator of anticoagulant activity of heparin in human
plasma. Comparing unmodified plasma samples of HRG-deficient mice and wild-type mice, we
determined that HRGmay antagonize antithrombin activity in vivo.
4.2.2.3 Effect of HRG on Fibrinogen level
It is known that HRG interacts with fibrinogen in vitro (Leung, 1986). ´erefore we meas-
ured fibrinogen in plasma of Hrg+/+ Hrg+/- and Hrg-/- mice. We observed principally higher
fibrinogen levels in male than in female mice independently of the genotype. ´is sex-specific
differences has been already described for 129/B6 wild-type mice (mouse phenome database;
http://aretha.jax.org/pub-cgi/phenome/mpdcgi?rtn=docs/home). HRG-deficient mice of both
sexes had elevated plasma fibrinogen levels, most clearly and statistically highly significant in
femaleHrg-/- mice, which had 35 %more plasma fibrinogen than age and sex-matched wild-type
and heterozygous mice. ´is is the first demonstration in vivo that HRG levels in blood might
also influence the level of the most abundant protein of the blood coagulation cascade, possibly
associated with enhanced plasma coagulation. Although the molecular mechanism of this ap-
parent up-regulation is unknown, similar observations exist in human patients. ´ree cases of
congenital HRG-deficiency have been reported to date (Shigekiyo et al., 1993, 2000; Souto et al.,
1996).
Strikingly, all patients suffering from embolism were women. One patient with the HRG
Tokushima 2 allele had only 50 % of the normal HRG plasma level, and had associated elevated
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fibrinogen (Shigekiyo et al., 2000). HRG level is known to be regulated by estrogen (Jespersen and
Klu, 1982). ´ese results indicate that HRGmight regulate the fibrinogen level in a hormone-
dependent manner.
4.2.3 Effect of HRG on Fibrinolytic system
One may ask the question, why a thrombophilic phenotype was not observed in HRG-deficient
mice. Firstly, we determined that the prothrombin time is shorter and the antithrombin activity
is higher in HRG-deficient plasma (see figure 3.16 on page 49 and figure 3.18 on page 51) and
therefore HRG should be considered to act modulation of anticoagulaant and procoagulant.
Secondly, it is known that HRG binds to plasminogen in plasma and in this context it is supposed
to act antifibrinolytic (Lijnen et al., 1980). ´erefore the antifibrinolytic influence of HRG would
be abrogated inHrg-/- mice. ´is view is compatible with a report that poly-histidine a surrogate of
the histidine-rich region of HRG down-regulated fibrinolysis by suppressing plasmin interaction
with fibrin (Chu andMathews, 2003). To elucidate if this antifibrinolytic effect can be compensated
by elevated fibrinogen level, we measured the fibrinolytic activity in blood samples ofHrg+/+ and
Hrg-/- mice. ´e spontaneous whole blood clot lysis in blood fromHrg-/- mice was consistently
and significantly enhanced compared to blood fromHrg+/- and in particularHrg+/+ mice.
´e combined results from this and the previous finding indicate that HRGmay exert both
anti-coagulant and anti-fibrinolytic effects in vivo though these effects do not cause a distinct
phenotype in unchallenged HRG-deficient mice in vivo. Pending a detailed histological analysis
of microthrombi in HRG null mice one should keep in mind that mice are viable even in the
complete absence of plasminogen although they suffer thrombophilia and associated wasting
disease and increased mortality (Bugge et al., 1995).
Recently, it was reported that the fibrinolytic system is related to inflammation, invasion
and metastasis of cancer cells, ovulation, angiogenesis and cerebral function (Cesarman-Maus
and Hajjar, 2005). HRGmay also regulate such a function through binding to plasminogen and
plasmin.
4.2.4 Effect of HRG on Bleeding time
Apart from plasmatic coagulation, hemostasis can also be modulated on the level of platelets,
which are known to contain HRG (Leung et al., 1983). To determine the effect of HRG-deficiency
on platelet functionwemeasured the bleeding time following tail tip amputation. Consistently, the
bleeding time inHrg-/- mice was significantly shorter than inHrg+/+ mice. ´is result suggested
that HRGmay inhibit platelet adhesion and aggregation in addition to its influence on plasmatic
hemostasis.
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Lerch et al. reported that HRG binds to activated platelets (Lerch et al., 1988) especially in the
presence of Zn2+ (Horne et al., 2001). HRG inactivates platelet thrombospondin (TSP), a strong
promoter of platelet aggregation by complex formation (Leung et al., 1984). Hence the inhibition
of platelet adhesion and aggregation by HRGmay be caused by an interaction of HRG with TSP.
To confim this hypothesis, we started to analyze platelet aggregation in vitro.
4.2.5 Effect of HRG on platelet aggregation activity
To confirm if the HRG-deficiency influences platelet aggregation, we analyzed the platelet aggreg-
ation activity in mouse platelet-rich plasma. ´e activity induced by low dose thrombin, ADP
and collagen was significantly higher inHrg-/- mice than inHrg+/+ mice. ´ese results suggested
that HRG may function as an anti-platelet aggregation factor in vivo. ´e platelet aggregation
activity was also measured with washed platelet, but in contrast to unwashed platelet there were
no gross differences between Hrg-/- and Hrg+/+ mice platelets. Immunoblot analysis showed
that HRG protein was present in washed Hrg+/+ platelets but not in washed Hrg-/-. ´erefore
the functional difference between unwashed and washed platelets must be due to the loss of
surrounding plasma components (e.g. HRG, fibrinogen) but not to difference in platelet function.
´is point needs further clarification using mixed and matched plasma/platelet combinations as
well as reconstitutedHrg-/- plasma. ´e different results between studies with platelet-rich plasma
and washed platelets points to the absence of one important factor in the latter study, which is
normally interacting with HRG. One candidate which occurs in high plasma concentrations and
is known to bind to HRG is fibrinogen (Leung, 1986). Fibrinogen is also known as a ligand of
integrin αIIbβ3 (also known as the glycoprotein (GP) GPIIb-IIIa.) which is located on the surface
of platelets (Charo et al., 1987). ´e interaction between fibrinogen and integrin αIIbβ3 promotes
platelet aggregation (see figure 1.8 on page 16).
Our results point to a regulatory role of HRG concerning the fibrinogen level. In fact, the
fibrinogen level was significantly higher inHrg-/- mice than in wild-type mice plasma. Maybe
HRG exerts also a regulatory function on the activity or availability of fibrinogen by blocking
the interaction between fibrinogen and integrin αIIbβ3. To verify this hypothesis further platelet
aggregation studies are needed.
Anti-platelet therapy is a very important approach for patients with several forms of cardi-
ovascular diseases associated with an increased risk of thrombosis. ´ere are potentially a large
number of adhesive proteins and receptors contributing to thrombus formation. However, in
only a few cases especially fibrinogen, vWF and collagen strong evidence exists for their direct
involvement in occlusive thrombus formation. ´e importance of blocking fibrinogen binding to
GPIIb-IIIa is well established as one of the targets in the antithrombotics research field (Jackson
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and Schoenwaelder, 2003).
Ideally, antithrombotic approaches should target one or more processes that are cruicial for
pathological thrombosis, but which are less important for hemostasis. In general this depends
strongly on the therapeutic window of the antithrombotic drugs. In this context one feature of
HRG is of special interest in our effort to uncover the role of HRG in platelet activation and
aggregation, namely the binding of zinc. It was reported that HRG strongly binds to platelets only
in the presence of Zn2+ (Horne et al., 2001). ´e zinc concentration in platelets is estimated to
be ˆ500 µM (30-60 fold higher than plasma levels). Approximately 40 % of the platelet Zn2+ is
distributed in α granules from where it is released aer platelet stimulation (Gorodetsky et al.,
1993). To elucidate the mechanism and the zinc-dependence of HRG action as an antithrombotic
factor, further studies withHrg-/- platelets will be necessary.
4.2.6 Effect of HRG on inflammation
HRG as a regulator of hemostasis and fibrinolysis may participate in the wound healing process
due to its interaction with several components of hemostasis and fibrinolysis like prothrombin,
fibrinogen and plasminogen. To examine the impact of HRG-deficiency on wound healing, we
produced full thickness skin wounds inHrg-/- and wild-type mice. ´e wound areas were meas-
ured every day to investigate the kinetic of wound closure. In both, wild-type and HRG-deficient
mice the course of wound healing seemed to be similar and we could not detect any differences
concerning the kinetic of wound closure. Further histological and immunohistological investiga-
tions have to clarify if HRG deficiency affects processes in wound healing like epithelialization,
vascularization or migration of cells into the wound area.
4.3 Conclusion and Outlook
HRG is exquisitely sensitive to pH changes around the physiological blood pH and has been
termed apH sensor (Borza andMorgan, 1998). Wehypothesize thatHRGmaymodulate plasmatic
and platelet dependent hemostasis in a pH and zinc dependent fashion depending on the specific
requirements in different locations of the body that may require enhanced or attained blood
clotting. ´is hypothesis can now be tested using the HRG-deficient mice in various models of
wounding and hemostasis.
In summary, our first analyses ofHRG-deficientmice revealedmild, yet statistically significant
alterations in blood coagulation parameters. In a normal situation the lack of plasmaHRGmay be
physiologically silent. Pathophysiological challenges or the combinationwith genetic backgrounds
may however exacerbate this mild phenotype like in the case of fetuin-A, a related plasma protein
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(Schafer et al., 2003). ´e early process of wound healing, the inflammatory phase involves
processes as by hemostasis and inflammation. Tissue injury immediately leads to activation of the
coagulation cascade and to clot formation. Components of the fibrinolytic system are involved
in cell migratory events associated with tissue remodelling during wound healing. Deficiency
of components of the coagulation pathway or the fibrinolytic system can alter wound healing
processes differentially. In PAI-1-deficient mice the rate of wound healing was significantly
increased (Chan et al., 2001) whereas wound healing in plasminogen-deficient mice was severely
impaired (Bugge et al., 1995).
Healing time of skin wounds in fibrinogen-deficient mice was comparable to that of control
animals, with a remarkably similar final outcome but histological examination revealed distinct
differences in the process of tissue repair (Suh et al., 1995). ´e wound healing rate in Hrg-/-
showed no difference to wild-type animals but the further (immuno-) histological examinations
may reveal similar findings as seen in fibrinogen-deficient mice because these proteins interact
with each other.
In conclusion, we have cloned the mouseHrg gene and generated HRG-deficient mice. Our
initial characterization of HRG-deficient mice is compatible with an anti-coagulant and anti-
fibrinolytic role of HRG, but does not exclude additional functions like pH sensing (Borza and
Morgan, 1998), metal ion transport (Morgan, 1985) and modulation of the innate immune
response (Gorgani et al., 2002). More elaborate animal experiments involving wounding and
disseminated clotting will tell, if the mild differences in unchallenged animals reported here
become critical under pathophysiological conditions.
Especially the effect of the lack of HRG on fibrinogen binding to platelets will be investigated
next. In addition studies with washed wild-type platelets with and without plasma of wild-type
andHrg-/- mice will give clues about regulation of platelet activation by HRG.
´e further study will elucidate the effect of HRG on platelet signaling.
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Abbreviations
+/+ Wild-type.
+/- Heterozygous.
-/- Knockout.
129SvJ/B6 Hybridized mouse strain of 129SvJ and C57BL/6.
ADP Adenosine diphosphate.
AP-1 Activating protein-1.
BAC Bacterial artificial chromosome.
B6 Mouse strain of C57BL/6.
cAMP Cyclic adenosine monophosphate.
C1q Complement 1q.
CD Cluster of differentiation.
cDNA Complementary DNA.
C/EBP CCAAT-enhancer binding protein.
DTT Dithiothreitol.
ES cells Embryonic stem cells.
EDTA Ethylenediaminetetraacetic acid.
Fcγ R Receptors for the constant region (Fc) of IgG antibodies.
Fc-Fc Interaction between the constant region (Fc).
GAGs Glycosaminoglycan.
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Abbreviations
Hrg Genetic symbol of murin histidine-rich glycoprotein.
HRG Genetic symbol of human histidine-rich glycoprotein.
HPRG Histidine-proline rich glycoprotein.
H/P Histidine-Proline rich.
IgG Immunoglobulin G.
IIC Insoluble immune complexes.
kDa Kilo dalton.
kb Kilo base.
PAC P1-derived artificial chromosome.
PAGE Polyacrylamide gel electrophoresis.
PCR Polymerase chain reaction.
PEPCK Phosphoenolpyruvate carboxykinase.
pPAC4 PAC inserted vector.
RPCI21 Mouse strain of RPCI21.
SDS Sodium dodecyl sulfate.
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